Helicobacter pylori

Last updated

Contents

Helicobacter pylori
EMpylori.jpg
Electron micrograph of H. pylori possessing multiple flagella (negative staining)
Scientific classification OOjs UI icon edit-ltr.svg
Domain: Bacteria
Phylum: Campylobacterota
Class: "Campylobacteria"
Order: Campylobacterales
Family: Helicobacteraceae
Genus: Helicobacter
Species:
H. pylori
Binomial name
Helicobacter pylori
(Marshall et al. 1985) Goodwin et al., 1989
Synonyms
  • Campylobacter pyloriMarshall et al. 1985

Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, flagellated, helical bacterium. Mutants can have a rod or curved rod shape, and these are less effective. [1] [2] Its helical body (from which the genus name, Helicobacter , derives) is thought to have evolved in order to penetrate the mucous lining of the stomach, helped by its flagella, and thereby establish infection. [3] [2] The bacterium was first identified as the causal agent of gastric ulcers in 1983 by the Australian doctors Barry Marshall and Robin Warren. [4] [5]

Infection of the stomach with H. pylori is not the cause of illness itself; over half of the global population is infected but most are asymptomatic. [6] [7] Persistent colonization with more virulent strains can induce a number of gastric and extragastric disorders. [8] Gastric disorders due to infection begin with gastritis, inflammation of the stomach lining. [9] When infection is persistent the prolonged inflammation will become chronic gastritis. Initially this will be non-atrophic gastritis, but damage caused to the stomach lining can bring about the change to atrophic gastritis, and the development of ulcers both within the stomach itself or in the duodenum, the nearest part of the intestine. [9] At this stage the risk of developing gastric cancer is high. [10] However, the development of a duodenal ulcer has a lower risk of cancer. [11] Helicobacter pylori is a class 1 carcinogen, and potential cancers include gastric mucosa-associated lymphoid tissue (MALT) lymphomas and gastric cancer. [9] [10] Infection with H. pylori is responsible for around 89 per cent of all gastric cancers, and is linked to the development of 5.5 per cent of all cases of cancer worldwide. [12] [13] H. pylori is the only bacterium known to cause cancer. [14]

Extragastric complications that have been linked to H. pylori include anemia due either to iron-deficiency or vitamin B12 deficiency, diabetes mellitus, cardiovascular, and certain neurological disorders. [15] An inverse link has also been claimed with H. pylori having a positive protective effect on many disorders including asthma, esophageal cancer, IBD (including GERD and Crohn's disease) and other disorders. [15]

Some studies suggest that H. pylori plays an important role in the natural stomach ecology by influencing the type of bacteria that colonize the gastrointestinal tract. [16] [17] Other studies suggest that non-pathogenic strains of H. pylori may beneficially normalize stomach acid secretion, and regulate appetite. [18]

In 2023, it was estimated that about two-thirds of the world's population were infected with H. pylori, being more common in developing countries. [19] The prevalence has declined in many countries due to eradication treatments with antibiotics and proton-pump inhibitors, and with increased standards of living. [20] [21]

Microbiology

Helicobacter pylori is a species of gram-negative bacteria in the Helicobacter genus. [22] About half the world's population is infected with H. pylori but only a few strains are pathogenic. H pylori is a helical bacterium having a predominantly helical shape, also often described as having a spiral or S shape. [23] [24] Its helical shape is better suited for progressing through the viscous mucosa lining of the stomach, and is maintained by a number of enzymes in the cell wall's peptidoglycan. [1] The bacteria reach the less acidic mucosa by use of their flagella. [25] Three strains studied showed a variation in length from 2.8–3.3 μm but a fairly constant diameter of 0.55–0.58 μm. [23] H. pylori can convert from a helical to an inactive coccoid form, that may possibly become viable, known as viable but nonculturable (VBNC). [26]

Helicobacter pylori is microaerophilic – that is, it requires oxygen, but at lower concentration than in the atmosphere. It contains a hydrogenase that can produce energy by oxidizing molecular hydrogen (H2) made by intestinal bacteria. [27]

H. pylori can be demonstrated in tissue by Gram stain, Giemsa stain, H&E stain, Warthin-Starry silver stain, acridine orange stain, and phase-contrast microscopy. It is capable of forming biofilms. Biofilms help to hinder the action of antibiotics and can contribute to treatment failure. [28] [29]

To successfully colonize H. pylori uses many different virulence factors including oxidase, catalase, and urease. [30] Urease is the most abundant protein, its expression representing about 10% of the total protein weight. [31]

H. pylori possesses five major outer membrane protein families. [30] The largest family includes known and putative adhesins. The other four families are porins, iron transporters, flagellum-associated proteins, and proteins of unknown function. Like other typical gram-negative bacteria, the outer membrane of H. pylori consists of phospholipids and lipopolysaccharide (LPS). The O-antigen of LPS may be fucosylated and mimic Lewis blood group antigens found on the gastric epithelium. [30]

Genome

Helicobacter pylori consists of a large diversity of strains, and hundreds of genomes have been completely sequenced. [32] [33] [34] The genome of the strain 26695 consists of about 1.7 million base pairs, with some 1,576 genes. [35] [36] The pan-genome, that is the combined set of 30 sequenced strains, encodes 2,239 protein families (orthologous groups OGs). [37] Among them, 1,248 OGs are conserved in all the 30 strains, and represent the universal core. The remaining 991 OGs correspond to the accessory genome in which 277 OGs are unique to one strain. [38]

There is an unusually high number of restriction modification systems in the genome of H. pylori. [39] These provide a defence against bacteriophages. [39]

Transcriptome

Single-cell transcriptomics using single-cell RNA-Seq gave the complete transcriptome of H. pylori which was published in 2010. This analysis of its transcription confirmed the known acid induction of major virulence loci, including the urease (ure) operon and the Cag pathogenicity island. [40] A total of 1,907  transcription start sites 337 primary operons, and 126 additional suboperons, and 66 monocistrons were identified. Until 2010, only about 55 transcription start sites (TSSs) were known in this species. 27% of the primary TSSs are also antisense TSSs, indicating that – similar to E. coli – antisense transcription occurs across the entire H. pylori genome. At least one antisense TSS is associated with about 46% of all open reading frames, including many housekeeping genes. [40] About 50% of the 5′ UTRs (leader sequences) are 20–40 nucleotides (nt) in length and support the AAGGag motif located about 6 nt (median distance) upstream of start codons as the consensus Shine–Dalgarno sequence in H. pylori. [40]

Proteome

The proteome of H. pylori has been systematically analyzed and more than 70% of its proteins have been detected by mass spectrometry, and other methods. About 50% of the proteome has been quantified, informing of the number of protein copies in a typical cell. [41]

Studies of the interactome have identified more than 3000 protein-protein interactions. This has provided information of how proteins interact with each other, either in stable protein complexes or in more dynamic, transient interactions, which can help to identify the functions of the protein. This in turn helps researchers to find out what the function of uncharacterized proteins is, e.g. when an uncharacterized protein interacts with several proteins of the ribosome (that is, it is likely also involved in ribosome function). About a third of all ~1,500 proteins in H. pylori remain uncharacterized and their function is largely unknown. [42]

Infection

Diagram of stages of ulcer development H pylori ulcer diagram en.png
Diagram of stages of ulcer development

An infection with Helicobacter pylori can either have no symptoms even when lasting a lifetime, or can harm the stomach and duodenal linings by inflammatory responses induced by several mechanisms associated with a number of virulence factors. Colonization can initially cause H. pylori induced gastritis, an inflammation of the stomach lining that became a listed disease in ICD11. [43] [44] [45] This will progress to chronic gastritis if left untreated. Chronic gastritis may lead to atrophy of the stomach lining, and the development of peptic ulcers (gastric or duodenal). These changes may be seen as stages in the development of gastric cancer, known as Correa's cascade. [46] [47] Extragastric complications that have been linked to H. pylori include anemia due either to iron-deficiency or vitamin B12 deficiency, diabetes mellitus, cardiovascular, and certain neurological disorders. [15]

Peptic ulcers are a consequence of inflammation that allows stomach acid and the digestive enzyme pepsin to overwhelm the protective mechanisms of the mucous membranes. The location of colonization of H. pylori, which affects the location of the ulcer, depends on the acidity of the stomach. [48] In people producing large amounts of acid, H. pylori colonizes near the pyloric antrum (exit to the duodenum) to avoid the acid-secreting parietal cells at the fundus (near the entrance to the stomach). [30] G cells express relatively high levels of PD-L1 that protects these cells from H. pylori-induced immune destruction. [49] In people producing normal or reduced amounts of acid, H. pylori can also colonize the rest of the stomach.

Diagram showing parts of the stomach 2414 Stomach.jpg
Diagram showing parts of the stomach

The inflammatory response caused by bacteria colonizing near the pyloric antrum induces G cells in the antrum to secrete the hormone gastrin, which travels through the bloodstream to parietal cells in the fundus. [50] Gastrin stimulates the parietal cells to secrete more acid into the stomach lumen, and over time increases the number of parietal cells, as well. [51] The increased acid load damages the duodenum, which may eventually lead to the formation of ulcers.

Helicobacter pylori is a class I carcinogen, and potential cancers include gastric mucosa-associated lymphoid tissue (MALT) lymphomas and gastric cancer. [9] [10] [52] Less commonly diffuse large B-cell lymphoma of the stomach is a risk. [53] Infection with H. pylori is responsible for around 89 per cent of all gastric cancers, and is linked to the development of 5.5 per cent of all cases of cancer worldwide. [12] [13] Although the data varies between different countries, overall about 1% to 3% of people infected with Helicobacter pylori develop gastric cancer in their lifetime compared to 0.13% of individuals who have had no H. pylori infection. [54] [30] H. pylori-induced gastric cancer is the third highest cause of worldwide cancer mortality as of 2018. [55] Because of the usual lack of symptoms, when gastric cancer is finally diagnosed it is often fairly advanced. More than half of gastric cancer patients have lymph node metastasis when they are initially diagnosed. [56]

Micrograph of H. pylori colonizing the stomach lining Helicobacter pylori2.jpg
Micrograph of H. pylori colonizing the stomach lining

Chronic inflammation that is a feature of cancer development is characterized by infiltration of neutrophils and macrophages to the gastric epithelium, which favors the accumulation of pro-inflammatory cytokines, reactive oxygen species (ROS) and reactive nitrogen species (RNS) that cause DNA damage. [57] The oxidative DNA damage and levels of oxidative stress can be indicated by a biomarker, 8-oxo-dG. [57] [58] Other damage to DNA includes double-strand breaks. [59]

Small gastric and colorectal polyps are adenomas that are more commonly found in association with the mucosal damage induced by H. pylori gastritis. [60] [61] Larger polyps can in time become cancerous. [62] [60] A modest association of H. pylori has been made with the development of colorectal cancers but as of 2020 causality had yet to be proved. [63] [62]

Signs and symptoms

Most people infected with H. pylori never experience any symptoms or complications, but will have a 10% to 20% risk of developing peptic ulcers or a 0.5% to 2% risk of stomach cancer. [7] [64] H. pylori induced gastritis may present as acute gastritis with stomach ache, nausea, and ongoing dyspepsia (indigestion) that is sometimes accompanied by depression and anxiety. [7] [65] Where the gastritis develops into chronic gastritis, or an ulcer, the symptoms are the same and can include indigestion, stomach or abdominal pains, nausea, bloating, belching, feeling hunger in the morning, feeling full too soon, and sometimes vomiting, heartburn, bad breath, and weight loss. [66] [67]

Complications of an ulcer can cause severe signs and symptoms such as black or tarry stool indicative of bleeding into the stomach or duodenum; blood - either red or coffee-ground colored in vomit; persistent sharp or severe abdominal pain; dizziness, and a fast heartbeat. [66] [67] Bleeding is the most common complication. In cases caused by H. pylori there was a greater need for hemostasis often requiring gastric resection. [68] Prolonged bleeding may cause anemia leading to weakness and fatigue. Inflammation of the pyloric antrum, which connects the stomach to the duodenum, is more likely to lead to duodenal ulcers, while inflammation of the corpus may lead to a gastric ulcer.

Stomach cancer can cause nausea, vomiting, diarrhoea, constipation, and unexplained weight loss. [69] Gastric polyps are adenomas that are usually asymptomatic and benign, but may be the cause of dyspepsia, heartburn, bleeding from the stomach, and, rarely, gastric outlet obstruction. [60] [70] Larger polyps may have become cancerous. [60] Colorectal polyps may be the cause of rectal bleeding, anemia, constipation, diarrhea, weight loss, and abdominal pain. [71]

Pathophysiology

Virulence factors help a pathogen to evade the immune response of the host, and to successfully colonize. The many virulence factors of H. pylori include its flagella, the production of urease, adhesins, serine protease HtrA (high temperature requirement A), and the major exotoxins CagA and VacA. [28] [72] The presence of VacA and CagA are associated with more advanced outcomes. [73] CagA is an oncoprotein associated with the development of gastric cancer. [6]

Diagram of H. pylori and associated virulence factors H pylori virulence factors en.png
Diagram of H. pylori and associated virulence factors
Diagram showing how H. pylori reaches the epithelium of the stomach Ulcer-causing Bacterium (H.Pylori) Crossing Mucus Layer of Stomach.jpg
Diagram showing how H. pylori reaches the epithelium of the stomach

H. pylori infection is associated with epigenetically reduced efficiency of the DNA repair machinery, which favors the accumulation of mutations and genomic instability as well as gastric carcinogenesis. [74] It has been shown that expression of two DNA repair proteins, ERCC1 and PMS2, was severely reduced once H. pylori infection had progressed to cause dyspepsia. [75] Dyspepsia occurs in about 20% of infected individuals. [76] Epigenetically reduced protein expression of DNA repair proteins MLH1, MGMT and MRE11 are also evident. Reduced DNA repair in the presence of increased DNA damage increases carcinogenic mutations and is likely a significant cause of gastric carcinogenesis. [58] [77] [78] These epigenetic alterations are due to H. pylori-induced methylation of CpG sites in promoters of genes [77] and H. pylori-induced altered expression of multiple microRNAs. [78]

Two related mechanisms by which H. pylori could promote cancer have been proposed. One mechanism involves the enhanced production of free radicals near H. pylori and an increased rate of host cell mutation. The other proposed mechanism has been called a "perigenetic pathway", [79] and involves enhancement of the transformed host cell phenotype by means of alterations in cell proteins, such as adhesion proteins. H. pylori has been proposed to induce inflammation and locally high levels of tumor necrosis factor (TNF), (also known as tumor necrosis factor alpha (TNFα) and/or interleukin 6 (IL-6). According to the proposed perigenetic mechanism, inflammation-associated signaling molecules, such as TNF, can alter gastric epithelial cell adhesion and lead to the dispersion and migration of mutated epithelial cells without the need for additional mutations in tumor suppressor genes, such as genes that code for cell adhesion proteins. [80]

Flagellum

The first virulence factor of Helicobacter pylori that enables colonization is its flagellum. [81] H. pylori has from two to seven flagella at the same polar location which gives it a high motility. The flagellar filaments are about 3 μm long, and composed of two copolymerized flagellins, FlaA and FlaB, coded by the genes flaA, and flaB. [25] [72] The minor flagellin FlaB is located in the proximal region and the major flagellin FlaA makes up the rest of the flagellum. [82] The flagella are sheathed in a continuation of the bacterial outer membrane which gives protection against the gastric acidity. The sheath is also the location of the origin of the outer membrane vesicles that gives protection to the bacterium from bacteriophages. [82]

H. pylori is able to sense the less acidic pH gradient in the mucus, and guided by chemotaxis uses its flagella to move towards it. Once there it can burrow through to the underlying epithelial cell layer. [82] H. pylori travels through the mucosa to the gastric pits where they colonise and live inside the gastric glands. [83] Occasionally the bacteria are found inside the epithelial cells themselves. [84]

Urease

H. pylori urease enzyme diagram H. pylori urease enzyme diagram.svg
H. pylori urease enzyme diagram

In addition to using chemotaxis to avoid areas of low pH (high acidity), H. pylori also neutralizes the acid in its environment by producing large amounts of urease, an enzyme which breaks down the urea present in the stomach to carbonic acid and ammonia. These react with the strong acids in the environment to produce a neutralized area around H. pylori. [85] Helicobacter pylori is one of the few known types of bacterium that has a urea cycle which is uniquely configured in the bacterium. [86] 10% of the cell is of nitrogen a balance that needs to be maintained. Any excess is stored in urea excreted in the urea cycle. [86]

A final stage enzyme in the urea cycle is arginase an enzyme that is crucial to the pathogenesis of H. pylori. Arginase produces ornithine and urea that the enzyme urease breaks down into carbonic acid and ammonia. Urease is the bacterium’s most abundant protein accounting for 10–15% of the bacterium's total protein content. Its expression is not only required for establishing initial colonization in the breakdown of urea to carbonic acid and ammonia but is essential for maintaining chronic infection. [87] [64] Ammonia reduces the stomach acidity allowing the bacteria to become locally established. Arginase promotes the persistence of infection by consuming arginine; arginine is used by macrophages to produce nitric oxide which has a strong antimicrobial effect. [86] [88] The ammonia produced to regulate pH is toxic to epithelial cells. [89]

Adhesins

H. pylori must make attachment with the epithelial cells to prevent its being swept away with the constant movement and renewal of the mucus. To give them this adhesion, bacterial outer membrane proteins as virulence factors called adhesins are produced. [90] BabA (blood group antigen binding adhesin) is most important during initial colonization, and SabA is important in persistence. BabA attaches to glycans and mucins in the epithelium. [90] BabA (coded for by the babA2 gene) also binds to the Lewis b antigen displayed on the surface of the epithelial cells. [91] Adherence via BabA is acid sensitive and can be fully reversed by a decreased pH. It has been proposed that BabA's acid responsiveness enables adherence while also allowing an effective escape from an unfavorable environment such as a low pH that is harmful to the organism. [92] SabA binds to increased levels of sialyl-Lewis X antigen expressed on gastric mucosa. [93]

Cholesterol glucoside

The outer membrane contains cholesterol glucoside, a sterol glucoside that H. pylori glycosylates from the cholesterol in the gastric gland cells, and inserts it into its outer membrane. [85] This cholesterol glucoside is important for membrane stability, morphology and immune evasion, and is rarely found in other bacteria. [94] [95]

The enzyme responsible for this is cholesteryl α-glucosyltransferase (αCgT) or (Cgt) encoded by the HP0421 gene. [96] A major effect of the depletion of host cholesterol by Cgt is to disrupt cholesterol-rich lipid rafts in the epithelial cells. Lipid rafts are involved in cell signalling and their disruption causes a reduction in the immune inflammatory response particularly by reducing interferon gamma. [97] Cgt is also secreted by the type IV secretion system, and is secreted in a selective way so that gastric niches where the pathogen can thrive are created. [96] Its lack has been shown to give vulnerability from environmental stress to bacteria, and also to disrupt CagA mediated interactions. [85]

Catalase

Colonization induces an intense anti-inflammatory response as a first-line immune system defence. Phagocytic leukocytes and monocytes infiltrate the site of infection, and antibodies are produced. [98] H. pylori is able to adhere to the surface of the phagocytes and impede their action. This is responded to by the phagocyte in the generation and release of oxygen metabolites into the surrounding space. H. pylori can survive this response by the activity of catalase at its attachment to the phagocytic cell surface. Catalase decomposes hydrogen peroxide into water and oxygen, protecting the bacteria from toxicity. Catalase has been shown to almost completely inhibit the phagocytic oxidative response. [98] It is coded for by the gene katA. [99]

Tipα

TNF-inducing protein alpha (Tipα) is a carcinogenic protein encoded by HP0596 unique to H. pylori that induces the expression of tumor necrosis factor. [80] [100] Tipα enters gastric cancer cells where it binds to cell surface nucleolin, and induces the expression of vimentin. Vimentin is important in the epithelial–mesenchymal transition associated with the progression of tumors. [101]

CagA

CagA (cytotoxin-associated antigen A) is a major virulence factor for H. pylori, an oncoprotein that is encoded by the cagA gene. Bacterial strains with the cagA gene are associated with the ability to cause ulcers, MALT lymphomas, and gastric cancer. [102] [103] The cagA gene codes for a relatively long (1186-amino acid) protein. The cag pathogenicity island (PAI) has about 30 genes, part of which code for a complex type IV secretion system. The low GC-content of the cag PAI relative to the rest of the Helicobacter genome suggests the island was acquired by horizontal transfer from another bacterial species. [36] The serine protease HtrA also plays a major role in the pathogenesis of H. pylori. The HtrA protein enables the bacterium to transmigrate across the host cells' epithelium, and is also needed for the translocation of CagA. [104]

The virulence of H. pylori may be increased by genes of the cag pathogenicity island; about 50–70% of H. pylori strains in Western countries carry it. [105] Western people infected with strains carrying the cag PAI have a stronger inflammatory response in the stomach and are at a greater risk of developing peptic ulcers or stomach cancer than those infected with strains lacking the island. [30] Following attachment of H. pylori to stomach epithelial cells, the type IV secretion system expressed by the cag PAI "injects" the inflammation-inducing agent, peptidoglycan, from their own cell walls into the epithelial cells. The injected peptidoglycan is recognized by the cytoplasmic pattern recognition receptor (immune sensor) Nod1, which then stimulates expression of cytokines that promote inflammation. [106]

The type-IV secretion apparatus also injects the cag PAI-encoded protein CagA into the stomach's epithelial cells, where it disrupts the cytoskeleton, adherence to adjacent cells, intracellular signaling, cell polarity, and other cellular activities. [107] Once inside the cell, the CagA protein is phosphorylated on tyrosine residues by a host cell membrane-associated tyrosine kinase (TK). CagA then allosterically activates protein tyrosine phosphatase/protooncogene Shp2. [108] These proteins are directly toxic to cells lining the stomach and signal strongly to the immune system that an invasion is under way. As a result of the bacterial presence, neutrophils and macrophages set up residence in the tissue to fight the bacteria assault. [109] Pathogenic strains of H. pylori have been shown to activate the epidermal growth factor receptor (EGFR), a membrane protein with a TK domain. Activation of the EGFR by H. pylori is associated with altered signal transduction and gene expression in host epithelial cells that may contribute to pathogenesis. A C-terminal region of the CagA protein (amino acids 873–1002) has also been suggested to be able to regulate host cell gene transcription, independent of protein tyrosine phosphorylation. [103] A great deal of diversity exists between strains of H. pylori, and the strain that infects a person can predict the outcome.

VacA

VacA (vacuolating cytotoxin auto transporter) is another major virulence factor encoded by the vacA gene. [110] All strains of H. pylori carry this gene but there is much diversity, and only 50% produce the encoded cytotoxin. [87] [31] The four main subtypes of vacA are s1/m1, s1/m2, s2/m1, and s2/m2. s1/m1 and s1/m2 are known to cause an increased risk of gastric cancer. [111] VacA is an oligomeric protein complex that causes a progressive vacuolation in the epithelial cells leading to their death. [112] The vacuolation has also been associated with promoting intracellular reservoirs of H. pylori by disrupting the calcium channel cell membrane TRPML1. [113] VacA has been shown to increase the levels of COX2, an up-regulation that increases the production of a prostaglandin indicating a strong host cell inflammatory response. [112] [114]

Outer membrane proteins and vesicles

About 4% of the genome encodes for outer membrane proteins that can be grouped into five families. [115] The largest family includes bacterial adhesins. The other four families are porins, iron transporters, flagellum-associated proteins, and proteins of unknown function. Like other typical gram-negative bacteria, the outer membrane of H. pylori consists of phospholipids and lipopolysaccharide (LPS). The O-antigen of LPS may be fucosylated and mimic Lewis blood group antigens found on the gastric epithelium. [30]

H. pylori forms blebs from the outer membrane that pinch off as outer membrane vesicles to provide an alternative delivery system for virulence factors including CagA. [85]

A Helicobacter cysteine-rich protein HcpA is known to trigger an immune response, causing inflammation. [116] A Helicobacter pylori virulence factor DupA is associated with the development of duodenal ulcers. [117]

Mechanisms of tolerance

In the stomach H. pylori has to not only survive the harsh gastric acidity but also the constant sweeping of mucus by continuous peristalsis, and phagocytic attack accompanied by the release of reactive oxygen species. [118] The need for survival has led to the development of different mechanisms of tolerance that enable their persistence. [119] Stress conditions activate bacterial response mechanisms that are regulated by proteins expressed by regulator genes. [119] The oxidative stress can induce potentially lethal mutagenic DNA adducts in its genome. Surviving this DNA damage is supported by transformation-mediated recombinational repair, that contributes to successful colonization. [120] [121] An overall response to multiple stressors can result from an interaction of the mechanisms. The mechanisms of tolerance and persistence can also help to overcome the effects of antibiotics. [119]

An effective sustained colonization response is the formation of a biofilm. Layers of aggregated bacteria form a biofilm. Cells in the deep layers are nutritionally deprived, and enter the coccoid dormant-like state. Some of these cells will be antibiotic resistant, and may remain in the host as persister cells. Following eradication the persister cells can cause a recurrence of the infection. [122] [123]

Transformation (the transfer of DNA from one bacterial cell to another through the intervening medium) appears to be part of an adaptation for DNA repair. H. pylori is naturally competent for transformation. While many organisms are competent only under certain environmental conditions, such as starvation, H. pylori is competent throughout logarithmic growth. [124] All organisms encode genetic programs for response to stressful conditions including those that cause DNA damage. [124] In H. pylori, homologous recombination is required for repairing double-strand breaks (DSBs). The AddAB helicase-nuclease complex resects DSBs and loads RecA onto single-strand DNA (ssDNA), which then mediates strand exchange, leading to homologous recombination and repair. The requirement of RecA plus AddAB for efficient gastric colonization suggests, in the stomach, H. pylori is either exposed to double-strand DNA damage that must be repaired or requires some other recombination-mediated event. In particular, natural transformation is increased by DNA damage in H. pylori, and a connection exists between the DNA damage response and DNA uptake in H. pylori, [124] suggesting natural competence contributes to persistence of H. pylori in its human host and explains the retention of competence in most clinical isolates. H. pylori has much greater rates of recombination, and mutation than other bacteria. [3] Genetically different strains can be found in the same host, and also in different regions of the stomach. [125]

RuvC protein is essential to the process of recombinational repair, since it resolves intermediates in this process termed Holliday junctions. H. pylori mutants that are defective in RuvC have increased sensitivity to DNA-damaging agents and to oxidative stress, exhibit reduced survival within macrophages, and are unable to establish successful infection in a mouse model. [126] Similarly, RecN protein plays an important role in DSB repair in H. pylori. [127] An H. pylori recN mutant displays an attenuated ability to colonize mouse stomachs, highlighting the importance of recombinational DNA repair in survival of H. pylori within its host. [127]

Diagnosis

H. pylori colonized on the surface of regenerative epithelium (Warthin-Starry silver stain) Pylorigastritis.jpg
H. pylori colonized on the surface of regenerative epithelium (Warthin-Starry silver stain)

Colonization with H. pylori is not a disease in itself, but a condition associated with a number of stomach diseases. [30] Testing is recommended in cases of peptic ulcer disease or low-grade gastric MALT lymphoma; after endoscopic resection of early gastric cancer; for first-degree relatives with gastric cancer, and in certain cases of indigestion. Other indications that prompt testing for H. pylori include long term aspirin or other non-steroidal anti-inflammatory use, unexplained iron deficiency anemia, or in cases of immune thrombocytopenic purpura. [128] Several methods of testing exist, both invasive and non-invasive.

Non-invasive tests for H. pylori infection include serological tests for antibodies, stool tests, and urea breath tests. Carbon urea breath tests include the use of carbon-13, or a radioactive carbon-14 producing a labelled carbon dioxide that can be detected in the breath. [129] Carbon urea breath tests have a high sensitivity and specificity for the diagnosis of H. pylori. [129]

Proton-pump inhibitors and antibiotics should be discontinued for at least 30 days prior to testing for H. pylori infection or eradication, as both agents inhibit H. pylori growth and may lead to false negative results. [128] Testing to confirm eradication is recommended 30 days or more after completion of treatment for H. pylori infection. H. pylori breath testing or stool antigen testing are both reasonable tests to confirm eradication. [128] H. pylori serologic testing, including IgG antibodies, are not recommended as a test of eradication as they may remain elevated for years after successful treatment of infection. [128]

An endoscopic biopsy is an invasive means to test for H. pylori infection. Low-level infections can be missed by biopsy, so multiple samples are recommended. The most accurate method for detecting H. pylori infection is with a histological examination from two sites after endoscopic biopsy, combined with either a rapid urease test or microbial culture. [130] Generally, repeating endoscopy is not recommended to confirm H. pylori eradication, unless there are specific indications to repeat the procedure. [128]

Transmission

Helicobacter pylori is contagious, and transmission is through either the oral–oral route or the fecal–oral route, but is mainly associated with the oral–oral route. [7] Consistent with these transmission routes, the bacteria have been isolated from feces, saliva, and dental plaque. [131] H. pylori may also be transmitted orally by drinking contaminated water. [7] Transmission occurs mainly within families in developed nations, yet can also be acquired from the community in developing countries. [132]

Prevention

To prevent the development of H. pylori-related diseases when infection is suspected, antibiotic-based therapy regimens are recommended to eradicate the bacteria. [45] When successful the disease progression is halted. First line therapy is recommended if low-grade gastric MALT lymphoma is diagnosed, regardless of evidence of H. pylori. However, if a severe condition of atrophic gastritis with gastric lesions is reached antibiotic-based treatment regimens are not advised since such lesions are often not reversible and will progress to gastric cancer. [45] If the cancer is managed to be treated it is advised that an eradication program be followed to prevent a recurrence of infection, or reduce a recurrence of the cancer, known as metachronous. [45] [133] [134]

Due to H. pylori's role as a major cause of certain diseases (particularly cancers) and its consistently increasing resistance to antibiotic therapy, there is an obvious need for alternative treatments. [135] A vaccine targeted towards the development of gastric cancer including MALT lymphoma, would also prevent the development of gastric ulcers. [5] A vaccine that would be prophylactic for use in children, and one that would be therapeutic later are the main goals. Challenges to this are the extreme genomic diversity shown by H. pylori and complex host-immune responses. [135] [136]

Previous studies in the Netherlands, and in the US have shown that such a prophylactic vaccine programme would be ultimately cost-effective. [137] [138] However, as of late 2019 there have been no advanced vaccine candidates and only one vaccine in a Phase I clinical trial. Furthermore, development of a vaccine against H. pylori has not been a priority of major pharmaceutical companies. [139] A key target for potential therapy is the proton-gated urea channel, since the secretion of urease enables the survival of the bacterium. [140]

Treatment

Gastritis

Following Maastricht Consensus Reports, H. pylori gastritis, has been included in ICD11, and listed as Helicobacter pylori induced gastritis. [43] [44] [45] Initially the infection tends to be superficial, localised to the upper mucosal layers of the stomach. [141] The intensity of chronic inflammation is related to the cytotoxicity of the H. pylori strain. A greater cytotoxicity will result in the change from a non-atrophic gastritis to an atrophic gastritis with the loss of mucous glands. This condition is a prequel to the development of peptic ulcers and gastric adenocarcinoma. [141]

Various antibiotic plus proton-pump inhibitor drug regimens are used to eradicate the infection and thereby successfully treat the disorder [142] with triple-drug therapy consisting of clarithromycin, amoxicillin, and a proton-pump inhibitor given for 14–21 days often being considered first line treatment. [141]

Peptic ulcers

Once H. pylori is detected in a person with a peptic ulcer, the normal procedure is to eradicate it and allow the ulcer to heal. The standard first-line therapy is a 14-day "triple therapy" consisting of acid-suppressive therapy, most commonly proton-pump inhibitors, such as omeprazole, or less commonly potassium-competitive acid blockers, such as vonoprazan, combined with the antibiotics clarithromycin and amoxicillin. [143] [144] (The actions of proton pump inhibitors against H. pylori may reflect their direct bacteriostatic effect due to inhibition of the bacterium's P-type ATPase or urease. [145] ) Variations of the triple therapy have been developed over the years, such as using a different proton pump inhibitor, as with pantoprazole or rabeprazole, or replacing amoxicillin with metronidazole for people who are allergic to penicillin. [146] In areas with higher rates of clarithromycin resistance, other options are recommended. [147] Such a therapy has revolutionized the treatment of peptic ulcers and has made a cure to the disease possible. Previously, the only option was symptom control using antacids, H2-antagonists or proton pump inhibitors alone. [148] [149] Eradication of H. pylori is associated with a subsequent decreased risk of duodenal or gastric ulcer recurrence. [128]

Antibiotic resistance

Increasing antibiotic resistance is the main cause of initial treatment failure. Factors linked to resistance include mutations, efflux pumps, and the formation of biofilms. [150] [151] One of the main antibiotics used in eradication therapies is clarithromycin, but clarithromycin-resistant strains have become well-established and the use of alternative antibiotics need to be considered. Multidrug resistance has also increased. [151] Next generation sequencing is looked to for identifying initial specific antibiotic resistances that will help in targeting more effective treatment. [152]

In 2018 the WHO listed H. pylori as a high priority pathogen for the research and discovery of new drugs and treatments. [153] The increasing antibiotic resistance encountered has spurred interest in developing alternative therapies using a number of plant compounds. [154] [155] Plant compounds have fewer side effects than synthetic drugs. Most plant extracts contain a complex mix of components that may not act on their own as antimicrobials but can work together with antibiotics to enhance treatment and work towards overcoming resistance. [154] Plant compounds have a different mechanism of action that has proved useful in fighting antimicrobial resistance. Various compounds can act for example by inhibiting enzymes such as urease, and adhesions to the mucous membrane. [156] Sulfur-containing compounds from plants with high concentrations of polysulfides, coumarins, and terpenes have all been shown to be effective against H. pylori. [154]

Additional rounds of antibiotics may be used or other therapies. [157] [158] [159] In patients with any previous macrolide exposure or who are allergic to penicillin, a quadruple therapy that consisting of a proton pump inhibitor, bismuth, tetracycline, and a nitroimidazole for 10–14 days is a recommended first-line treatment option. [160] For the treatment of clarithromycin-resistant strains of H. pylori, the use of levofloxacin as part of the therapy has been suggested. [161] [162]

Probiotic yogurts containing lactic acid bacteria, Bifidobacteria and Lactobacillus exert a suppressive effect on H. pylori infection, and their use has been shown to improve the rates of eradication. [13] Some commensal intestinal bacteria as part of the gut microbiota produce butyrate that acts as a prebiotic and enhances the mucosal immune barrier. Their use as probiotics may help balance the gut dysbiosis that accompanies antibiotic use. [163] Some probiotic strains have been shown to have bactericidal and bacteriostatic activity against H. pylori, and also help to balance the gut dysbiosis. [164]

H. pylori is found in saliva and dental plaque. Its transmission is known to include oral-oral suggesting that the dental plaque may act as a reservoir for the bacteria. Periodontal therapy or scaling and root planing has therefore been suggested as an additional treatment to enhance eradication rates but more research is needed. [165]

Cancers

Stomach cancer

Helicobacter pylori is linked to the majority of gastric adenocarcinoma cases, and to the majority of non-cardia adenocarcinomas located at the gastroesophageal junction. [166] The treatment for this cancer is highly aggressive with even localized disease being treated sequentially with chemotherapy and radiotherapy before surgical resection. [167] Since this cancer, once developed, is independent of H. pylori infection, antibiotic-proton pump inhibitor regimens are not used in its treatment. [166]

Gastric MALT lymphoma and DLBCL

MALT lymphomas are malignancies of mucosa-associated lymphoid tissue. Early gastric MALTomas due to H. pylori may be successfully treated (70–95% of cases) with one or more eradication programs. [13] Some 50–80% of patients who experience eradication of the pathogen develop within 3–28 months a remission and long-term clinical control of their lymphoma. Radiation therapy to the stomach and surrounding (i.e. peri-gastric) lymph nodes has also been used to successfully treat these localized cases. Patients with non-localized (i.e. systemic Ann Arbor stage III and IV) disease who are free of symptoms have been treated with watchful waiting or, if symptomatic, with the immunotherapy drug, rituximab, (given for 4 weeks) combined with the chemotherapy drug, chlorambucil, for 6–12 months; 58% of these patients attain a 58% progression-free survival rate at 5 years. Frail stage III/IV patients have been successfully treated with rituximab or the chemotherapy drug, cyclophosphamide, alone. [168] Antibiotic-proton pump inhibitor eradication therapy and localized radiation therapy have been used successfully to treat H. pylori-positive MALT lymphomas of the rectum; however radiation therapy has given slightly better results and therefore been suggested to be the disease' preferred treatment. [169] However, the generally recognized treatment of choice for patients with systemic involvement uses various chemotherapy drugs often combined with rituximab.

A MALT lymphoma may rarely transform into a more aggressive diffuse large B-cell lymphoma (DLBCL). [170] Where this is associated with H. pylori infection the DLBCL is less aggressive and more amenable to treatment. [171] [172] [173] When limited to the stomach they have sometimes been successfully treated with H. pylori eradication programs. [53] [172] [174] [173] If unresponsive or showing a deterioration, a more conventional chemotherapy (CHOP), immunotherapy or local radiotherapy can be considered, and any of these or a combination have successfully treated these more advanced types. [172] [173]

Prognosis

Helicobacter pylori colonizes the stomach for decades in most people, and induces chronic gastritis, a long-lasting inflammation of the stomach. In most cases symptoms are never experienced but about 10–20% of those infected will ultimately develop gastric and duodenal ulcers, and have a possible 1–2% lifetime risk of gastric cancer. [64]

H. pylori thrives in a high salt diet, which is seen as an environmental risk factor for its association with gastric cancer. A diet high in salt enhances colonization, increases inflammation, increases the expression of H. pylori virulence factors, and intensifies chronic gastritis. [175] [176] Paradoxically extracts of kimchi a salted probiotic food has been found to have a preventive effect on H. pylori associated gastric carcinogenesis. [177]

In the absence of treatment, H. pylori infection, usually persists for life. [178] Infection may disappear in the elderly as the stomach's mucosa becomes increasingly atrophic and inhospitable to colonization. Some studies in young children up to two years of age, have shown that infection can be transient in this age group. [179] [180]

It is possible for H. pylori to re-establish in a person after eradication. This recurrence can be caused by the original strain (recrudescence), or be caused by a different strain (reinfection). A 2017 meta-analysis showed that the global per-person annual rates of recurrence, reinfection, and recrudescence is 4.3%, 3.1%, and 2.2% respectively. It is unclear what the main risk factors are. [181]

Mounting evidence suggests H. pylori has an important role in protection from some diseases. [15] The incidence of acid reflux disease, Barrett's esophagus, and esophageal cancer have been rising dramatically at the same time as H. pylori's presence decreases. [182] In 1996, Martin J. Blaser advanced the hypothesis that H. pylori has a beneficial effect by regulating the acidity of the stomach contents. [50] [182] The hypothesis is not universally accepted as several randomized controlled trials failed to demonstrate worsening of acid reflux disease symptoms following eradication of H. pylori. [183] [184] Nevertheless, Blaser has reasserted his view that H. pylori is a member of the normal gastric microbiota. [16] He postulates that the changes in gastric physiology caused by the loss of H. pylori account for the recent increase in incidence of several diseases, including type 2 diabetes, obesity, and asthma. [16] [185] His group has recently shown that H. pylori colonization is associated with a lower incidence of childhood asthma. [186]

Epidemiology

In 2023, it was estimated that about two-thirds of the world's population were infected with H. pylori infection, being more common in developing countries. [19] H. pylori infection is more prevalent in South America, Sub-Saharan Africa, and the Middle East. [142] The global prevalence declined markedly in the decade following 2010, with a particular reduction in Africa. [20]

The age when someone acquires this bacterium seems to influence the pathologic outcome of the infection. People infected at an early age are likely to develop more intense inflammation that may be followed by atrophic gastritis with a higher subsequent risk of gastric ulcer, gastric cancer, or both. Acquisition at an older age brings different gastric changes more likely to lead to duodenal ulcer. [178] Infections are usually acquired in early childhood in all countries. [30] However, the infection rate of children in developing nations is higher than in industrialized nations, probably due to poor sanitary conditions, perhaps combined with lower antibiotics usage for unrelated pathologies. In developed nations, it is currently uncommon to find infected children, but the percentage of infected people increases with age. The higher prevalence among the elderly reflects higher infection rates incurred in childhood. [30] In the United States, prevalence appears higher in African-American and Hispanic populations, most likely due to socioeconomic factors. [187] [188] The lower rate of infection in the West is largely attributed to higher hygiene standards and widespread use of antibiotics. Despite high rates of infection in certain areas of the world, the overall frequency of H. pylori infection is declining. [189] However, antibiotic resistance is appearing in H. pylori; many metronidazole- and clarithromycin-resistant strains are found in most parts of the world. [190]

History

Helicobacter pylori migrated out of Africa along with its human host around 60,000 years ago. [191] Research has shown that genetic diversity in H. pylori, like that of its host, decreases with geographic distance from East Africa. Using the genetic diversity data, researchers have created simulations that indicate the bacteria seem to have spread from East Africa around 58,000 years ago. Their results indicate modern humans were already infected by H. pylori before their migrations out of Africa, and it has remained associated with human hosts since that time. [192]

H. pylori was first discovered in the stomachs of patients with gastritis and ulcers in 1982 by Barry Marshall and Robin Warren of Perth, Western Australia. At the time, the conventional thinking was that no bacterium could live in the acid environment of the human stomach. In recognition of their discovery, Marshall and Warren were awarded the 2005  Nobel Prize in Physiology or Medicine. [193]

Before the research of Marshall and Warren, German scientists found spiral-shaped bacteria in the lining of the human stomach in 1875, but they were unable to culture them, and the results were eventually forgotten. [182] The Italian researcher Giulio Bizzozero described similarly shaped bacteria living in the acidic environment of the stomach of dogs in 1893. [194] Professor Walery Jaworski of the Jagiellonian University in Kraków investigated sediments of gastric washings obtained by lavage from humans in 1899. Among some rod-like bacteria, he also found bacteria with a characteristic spiral shape, which he called Vibrio rugula. He was the first to suggest a possible role of this organism in the pathogenesis of gastric diseases. His work was included in the Handbook of Gastric Diseases, but it had little impact, as it was published only in Polish. [195] Several small studies conducted in the early 20th century demonstrated the presence of curved rods in the stomachs of many people with peptic ulcers and stomach cancers. [196] Interest in the bacteria waned, however, when an American study published in 1954 failed to observe the bacteria in 1180 stomach biopsies. [197]

Interest in understanding the role of bacteria in stomach diseases was rekindled in the 1970s, with the visualization of bacteria in the stomachs of people with gastric ulcers. [198] The bacteria had also been observed in 1979, by Robin Warren, who researched it further with Barry Marshall from 1981. After unsuccessful attempts at culturing the bacteria from the stomach, they finally succeeded in visualizing colonies in 1982, when they unintentionally left their Petri dishes incubating for five days over the Easter weekend. In their original paper, Warren and Marshall contended that most stomach ulcers and gastritis were caused by bacterial infection and not by stress or spicy food, as had been assumed before. [199]

Some skepticism was expressed initially, but within a few years multiple research groups had verified the association of H. pylori with gastritis and, to a lesser extent, ulcers. [200] To demonstrate H. pylori caused gastritis and was not merely a bystander, Marshall drank a beaker of H. pylori culture. He became ill with nausea and vomiting several days later. An endoscopy 10 days after inoculation revealed signs of gastritis and the presence of H. pylori. These results suggested H. pylori was the causative agent. Marshall and Warren went on to demonstrate antibiotics are effective in the treatment of many cases of gastritis. In 1994, the National Institutes of Health stated most recurrent duodenal and gastric ulcers were caused by H. pylori, and recommended antibiotics be included in the treatment regimen. [201]

The bacterium was initially named Campylobacter pyloridis, then renamed C. pylori in 1987 (pylori being the genitive of pylorus , the circular opening leading from the stomach into the duodenum, from the Ancient Greek word πυλωρός, which means gatekeeper [202] ). [203] When 16S ribosomal RNA gene sequencing and other research showed in 1989 that the bacterium did not belong in the genus Campylobacter , it was placed in its own genus, Helicobacter from the Ancient Greek έλιξ (hělix) "spiral" or "coil". [202] [204]

In October 1987, a group of experts met in Copenhagen to found the European Helicobacter Study Group (EHSG), an international multidisciplinary research group and the only institution focused on H. pylori. [205] The Group is involved with the Annual International Workshop on Helicobacter and Related Bacteria, [206] (renamed as the European Helicobacter and Microbiota Study Group [207] ), the Maastricht Consensus Reports (European Consensus on the management of H. pylori), [143] [146] [208] [209] and other educational and research projects, including two international long-term projects:

Research

Results from in vitro studies suggest that fatty acids, mainly polyunsaturated fatty acids, have a bactericidal effect against H. pylori, but their in vivo effects have not been proven. [213]

A suitable vaccine for H.pylori, either prophylactic or therapeutic, is an ongoing research aim. [7] The Murdoch Children's Research Institute is working at developing a vaccine that instead of specifically targeting the bacteria, aims to inhibit the inflammation caused that leads to the associated diseases. [139]

Gastric organoids can be used as a model for the study of H. pylori pathogenesis. [90]

See also

Related Research Articles

<span class="mw-page-title-main">Urea breath test</span> Medical test for a bacteria infection

The urea breath test is a rapid diagnostic procedure used to identify infections by Helicobacter pylori, a spiral bacterium implicated in gastritis, gastric ulcer, and peptic ulcer disease. It is based upon the ability of H. pylori to convert urea to ammonia and carbon dioxide. Urea breath tests are recommended in leading society guidelines as a preferred non-invasive choice for detecting H. pylori before and after treatment.

Peptic ulcer disease is a break in the inner lining of the stomach, the first part of the small intestine, or sometimes the lower esophagus. An ulcer in the stomach is called a gastric ulcer, while one in the first part of the intestines is a duodenal ulcer. The most common symptoms of a duodenal ulcer are waking at night with upper abdominal pain, and upper abdominal pain that improves with eating. With a gastric ulcer, the pain may worsen with eating. The pain is often described as a burning or dull ache. Other symptoms include belching, vomiting, weight loss, or poor appetite. About a third of older people with peptic ulcers have no symptoms. Complications may include bleeding, perforation, and blockage of the stomach. Bleeding occurs in as many as 15% of cases.

<i>Helicobacter</i> Genus of bacteria

Helicobacter is a genus of gram-negative bacteria possessing a characteristic helical shape. They were initially considered to be members of the genus Campylobacter, but in 1989, Goodwin et al. published sufficient reasons to justify the new genus name Helicobacter. The genus Helicobacter contains about 35 species.

<span class="mw-page-title-main">Stomach cancer</span> Cancerous tumor originating in the stomach lining

Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach. Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes, including gastric adenocarcinomas. Lymphomas and mesenchymal tumors may also develop in the stomach. Early symptoms may include heartburn, upper abdominal pain, nausea, and loss of appetite. Later signs and symptoms may include weight loss, yellowing of the skin and whites of the eyes, vomiting, difficulty swallowing, and blood in the stool, among others. The cancer may spread from the stomach to other parts of the body, particularly the liver, lungs, bones, lining of the abdomen, and lymph nodes.

<span class="mw-page-title-main">Barry Marshall</span> Australian physician (born 1951)

Barry James Marshall is an Australian physician, Nobel Laureate in Physiology or Medicine, Professor of Clinical Microbiology and Co-Director of the Marshall Centre at the University of Western Australia. Marshall and Robin Warren showed that the bacterium Helicobacter pylori plays a major role in causing many peptic ulcers, challenging decades of medical doctrine holding that ulcers were caused primarily by stress, spicy foods, and too much acid. This discovery has allowed for a breakthrough in understanding a causative link between Helicobacter pylori infection and stomach cancer.

<span class="mw-page-title-main">Gastritis</span> Stomach disease

Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a long duration. There may be no symptoms but, when symptoms are present, the most common is upper abdominal pain. Other possible symptoms include nausea and vomiting, bloating, loss of appetite and heartburn. Complications may include stomach bleeding, stomach ulcers, and stomach tumors. When due to autoimmune problems, low red blood cells due to not enough vitamin B12 may occur, a condition known as pernicious anemia.

<span class="mw-page-title-main">Achlorhydria</span> Medical condition

Achlorhydria and hypochlorhydria refer to states where the production of hydrochloric acid in gastric secretions of the stomach and other digestive organs is absent or low, respectively. It is associated with various other medical problems.

<span class="mw-page-title-main">Atrophic gastritis</span> Medical condition

Atrophic gastritis is a process of chronic inflammation of the gastric mucosa of the stomach, leading to a loss of gastric glandular cells and their eventual replacement by intestinal and fibrous tissues. As a result, the stomach's secretion of essential substances such as hydrochloric acid, pepsin, and intrinsic factor is impaired, leading to digestive problems. The most common are vitamin B12 deficiency possibly leading to pernicious anemia; and malabsorption of iron, leading to iron deficiency anaemia. It can be caused by persistent infection with Helicobacter pylori, or can be autoimmune in origin. Those with autoimmune atrophic gastritis (Type A gastritis) are statistically more likely to develop gastric carcinoma, Hashimoto's thyroiditis, and achlorhydria.

<span class="mw-page-title-main">MALT lymphoma</span> Medical condition

MALT lymphoma is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT), frequently of the stomach, but virtually any mucosal site can be affected. It is a cancer originating from B cells in the marginal zone of the MALT.

<span class="mw-page-title-main">Martin J. Blaser</span> American academic

Martin J. Blaser is the director of the Center for Advanced Biotechnology and Medicine at Rutgers (NJ) Biomedical and Health Sciences and the Henry Rutgers Chair of the Human Microbiome and Professor of Medicine and Pathology and Laboratory Medicine at the Rutgers Robert Wood Johnson Medical School in New Jersey.

Timeline of peptic ulcer disease and <i>Helicobacter pylori</i>

This is a timeline of the events relating to the discovery that peptic ulcer disease and some cancers are caused by H. pylori. In 2005, Barry Marshall and Robin Warren were awarded the Nobel Prize in Physiology or Medicine for their discovery that peptic ulcer disease (PUD) was primarily caused by Helicobacter pylori, a bacterium with affinity for acidic environments, such as the stomach. As a result, PUD that is associated with H. pylori is currently treated with antibiotics used to eradicate the infection. For decades prior to their discovery, it was widely believed that PUD was caused by excess acid in the stomach. During this time, acid control was the primary method of treatment for PUD, to only partial success. Among other effects, it is now known that acid suppression alters the stomach milieu to make it less amenable to H. pylori infection.

<span class="mw-page-title-main">Carcinogenic bacteria</span>

Cancer bacteria are bacteria infectious organisms that are known or suspected to cause cancer. While cancer-associated bacteria have long been considered to be opportunistic, there is some evidence that bacteria may be directly carcinogenic. The strongest evidence to date involves the bacterium H. pylori and its role in gastric cancer.

Helicobacter pylori eradication protocols is a standard name for all treatment protocols for peptic ulcers and gastritis in the presence of Helicobacter pylori infection. The primary goal of the treatment is not only temporary relief of symptoms but also total elimination of H. pylori infection. Patients with active duodenal or gastric ulcers and those with a prior ulcer history should be tested for H. pylori. Appropriate therapy should be given for eradication. Patients with MALT lymphoma should also be tested and treated for H. pylori since eradication of this infection can induce remission in many patients when the tumor is limited to the stomach. Several consensus conferences, including the Maastricht Consensus Report, recommend testing and treating several other groups of patients but there is limited evidence of benefit. This includes patients diagnosed with gastric adenocarcinoma, patients found to have atrophic gastritis or intestinal metaplasia, as well as first-degree relatives of patients with gastric adenocarcinoma since the relatives themselves are at increased risk of gastric cancer partly due to the intrafamilial transmission of H. pylori. To date, it remains controversial whether to test and treat all patients with functional dyspepsia, gastroesophageal reflux disease, or other non-GI disorders as well as asymptomatic individuals.

<span class="mw-page-title-main">Infectious causes of cancer</span>

Estimates place the worldwide risk of cancers from infectious causes at 16.1%. Viral infections are risk factors for cervical cancer, 80% of liver cancers, and 15–20% of the other cancers. This proportion varies in different regions of the world from a high of 32.7% in Sub-Saharan Africa to 3.3% in Australia and New Zealand.

Helicobacter felis is a bacterial species in the Helicobacteraceae family, Campylobacterales order, Helicobacter genus. This bacterium is Gram-negative, microaerophilic, urease-positive, and spiral-shaped. Its type strain is CS1T. It can be pathogenic.

Helicobacter salomonis is a species within the Helicobacter genus of Gram-negative bacteria. Helicobacter pylori is by far the best known Helicobacter species primarily because humans infected with it may develop gastrointestinal tract diseases such as stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers of the nonlymphoma type, and various subtypes of extranodal marginal zone lymphomass, e.g. those of the stomach, small intestines, large intestines, and rectumn. H. pylori is also associated with the development of bile duct cancer and has been associated with a wide range of other diseases, although its role in the development of many of these other diseases requires further study. Humans infected with H. salomonis may develop some of the same gastrointestinal diseases viz., stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers that are not lymphomas, and extranodal marginal B cell lymphomas of the stomach. Other non-H. pylori Helicobacter species that are known to be associated with these gastrointestinal diseases are Helicobacter bizzozeronii, Helicobacter suis, Helicobacter felis, and Helicobacter heilmannii s.s. Because of their disease associations, these four Helicobacter species plus H. salomonis are often group together and termed Helicobacter heilmannii sensu lato.

Helicobacter heilmannii sensu lato refers to a group of bacterial species within the Helicobacter genus. The Helicobacter genus consists of at least 40 species of spiral-shaped flagellated, Gram-negative bacteria of which the by far most prominent and well-known species is Helicobacter pylori. H. pylori is associated with the development of gastrointestinal tract diseases such as stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers that are not lymphomas, and various subtypes of extranodal marginal zone lymphomas, e.g. those of the stomach, small intestines, large intestines, and rectumn. H. pylori has also been associated with the development of bile duct cancer and has been associated with a wide range of other diseases although its role in the development of many of these other diseases requires further study.

Helicobacter bizzozeronii is a species within the Helicobacter genus of Gram-negative bacteria. Helicobacter pylori is by far the best known Helicobacter species, primarily because humans infected with it may develop gastrointestinal tract diseases such as stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers of the nonlymphoma type, and various subtypes of extranodal marginal zone lymphomass, e.g. those of the stomach, small intestines, large intestines, and rectumn. H. pylori is also associated with the development of bile duct cancer and has been associated with a wide range of other diseases although its role in the development of many of these other diseases requires further study. Humans infected with H. bizzozeronii are prone to develop some of the same gastrointestinal diseases viz., stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers that are not lymphomas, and extranodal marginal B cell lymphomas of the stomach. Other non-H. pylori Helicobacter species that are known to be associated with these gastrointestinal diseases are Helicobacter felis, Helicobacter salomonis, Helicobacter suis, and Helicobacter heilmannii s.s. Because of their disease associations, these four Helicobacter species plus H. bizzozeronii are often grouped together and termed Helicobacter heilmannii sensu lato.

Helicobacter suis is a species within the Helicobacter genus of Gram-negative bacteria. Helicobacter pylori is by far the best known Helicobacter species, primarily because humans infected with it may develop gastrointestinal tract diseases such as stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers of the nonlymphoma type, and various subtypes of extranodal marginal zone lymphomass, e.g. those of the stomach, small intestines, large intestines, and rectumn. H. pylori is also associated with the development of bile duct cancer and has been associated with a wide range of other diseases although its role in the development of many of these other diseases requires further study. Humans infected with H. suis may develop some of the same gastrointestinal diseases - stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers that are not lymphomas, and extranodal marginal B cell lymphomas of the stomach. Other non-H. pylori Helicobacter species that are known to be associated with these gastrointestinal diseases are Helicobacter bizzozeronii, Helicobacter salomonis, Helicobacter felis, and Helicobacter heilmannii s.s. Because of their disease associations, these four Helicobacter species plus H. suis are often group together and termed Helicobacter heilmannii sensu lato.

Helicobacter heilmannii s.s. is a species within the Helicobacter genus of Gram negative bacteria. Helicobacter pylori is by far the best known Helicobacter species primarily because humans infected with it may develop gastrointestinal tract diseases such as stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers of the non-lymphoma type, and various subtypes of extranodal marginal zone lymphomass, e.g. those of the stomach, small intestines, large intestines, and rectumn. H. pylori is also associated with the development of bile duct cancer and has been associated with a wide range of other diseases although its role in the development of many of these other diseases requires further study. Humans infected with H. heilmannii s.s. may develop some of the same gastrointestinal diseases viz., stomach inflammation, stomach ulcers, duodenal ulcers, stomach cancers that are not lymphomas, and extranodal marginal B cell lymphomas of the stomach. Other non-H. pylori Helicobacter species that are known to be associated with these gastrointestinal diseases are Helicobacter bizzozeronii, Helicobacter suis, Helicobacter felis, and Helicobacter salomonis. Because of their disease associations, these four Helicobacter species plus H. heilmannii s.s. are often group together and termed Helicobacter heilmannii sensu lato.

References

  1. 1 2 Martínez LE, O'Brien VP, Leverich CK, Knoblaugh SE, Salama NR (July 2019). "Nonhelical Helicobacter pylori Mutants Show Altered Gland Colonization and Elicit Less Gastric Pathology than Helical Bacteria during Chronic Infection". Infect Immun. 87 (7). doi:10.1128/IAI.00904-18. PMC   6589060 . PMID   31061142.
  2. 1 2 Salama NR (April 2020). "Cell morphology as a virulence determinant: lessons from Helicobacter pylori". Curr Opin Microbiol. 54: 11–17. doi:10.1016/j.mib.2019.12.002. PMC   7247928 . PMID   32014717.
  3. 1 2 Rust M, Schweinitzer T, Josenhans C (2008). "Helicobacter Flagella, Motility and Chemotaxis". In Yamaoka, Y. (ed.). Helicobacter pylori: Molecular Genetics and Cellular Biology. Caister Academic Press. ISBN   978-1-904455-31-8. Archived from the original on 18 August 2016. Retrieved 1 April 2008.
  4. ↑ Warren JR, Marshall B (June 1983). "Unidentified curved bacilli on gastric epithelium in active chronic gastritis". Lancet. 1 (8336): 1273–5. doi:10.1016/S0140-6736(83)92719-8. PMID   6134060. S2CID   1641856.
  5. 1 2 FitzGerald R, Smith SM (2021). "An Overview of Helicobacter pylori Infection". Helicobacter Pylori. Methods Mol Biol. Vol. 2283. pp. 1–14. doi:10.1007/978-1-0716-1302-3_1. ISBN   978-1-0716-1301-6. PMID   33765303. S2CID   232365068.
  6. 1 2 "Helicobacter pylori (H. pylori) and Cancer - NCI". www.cancer.gov. 25 September 2013. Archived from the original on 19 October 2023. Retrieved 18 October 2023.
  7. 1 2 3 4 5 6 de Brito BB, da Silva FA, Soares AS, Pereira VA, Santos ML, Sampaio MM, et al. (October 2019). "Pathogenesis and clinical management of Helicobacter pylori gastric infection". World J Gastroenterol. 25 (37): 5578–5589. doi: 10.3748/wjg.v25.i37.5578 . PMC   6785516 . PMID   31602159.
  8. ↑ Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS (2021). "The interplay between Helicobacter pylori and gastrointestinal microbiota". Gut Microbes. 13 (1): 1–22. doi:10.1080/19490976.2021.1909459. PMC   8096336 . PMID   33938378.
  9. 1 2 3 4 Matsuo Y, Kido Y, Yamaoka Y (March 2017). "Helicobacter pylori Outer Membrane Protein-Related Pathogenesis". Toxins. 9 (3): 101. doi: 10.3390/toxins9030101 . PMC   5371856 . PMID   28287480.
  10. 1 2 3 Marghalani AM, Bin Salman TO, Faqeeh FJ, Asiri MK, Kabel AM (June 2020). "Gastric carcinoma: Insights into risk factors, methods of diagnosis, possible lines of management, and the role of primary care". J Family Med Prim Care. 9 (6): 2659–2663. doi: 10.4103/jfmpc.jfmpc_527_20 . PMC   7491774 . PMID   32984103.
  11. ↑ Koga Y (December 2022). "Microbiota in the stomach and application of probiotics to gastroduodenal diseases". World J Gastroenterol. 28 (47): 6702–6715. doi: 10.3748/wjg.v28.i47.6702 . PMC   9813937 . PMID   36620346.
  12. 1 2 Shin WS, Xie F, Chen B, Yu J, Lo KW, Tse GM, et al. (October 2023). "Exploring the Microbiome in Gastric Cancer: Assessing Potential Implications and Contextualizing Microorganisms beyond H. pylori and Epstein-Barr Virus". Cancers. 15 (20): 4993. doi: 10.3390/cancers15204993 . PMC   10605912 . PMID   37894360.
  13. 1 2 3 4 Violeta Filip P, Cuciureanu D, Sorina Diaconu L, Maria Vladareanu A, Silvia Pop C (2018). "MALT lymphoma: epidemiology, clinical diagnosis and treatment". Journal of Medicine and Life. 11 (3): 187–193. doi:10.25122/jml-2018-0035. PMC   6197515 . PMID   30364585.
  14. ↑ Ruggiero P (November 2014). "Use of probiotics in the fight against Helicobacter pylori". World J Gastrointest Pathophysiol. 5 (4): 384–91. doi: 10.4291/wjgp.v5.i4.384 . PMC   4231502 . PMID   25400981.
  15. 1 2 3 4 Santos ML, de Brito BB, da Silva FA, Sampaio MM, Marques HS, Oliveira E, et al. (July 2020). "Helicobacter pylori infection: Beyond gastric manifestations". World J Gastroenterol. 26 (28): 4076–4093. doi: 10.3748/wjg.v26.i28.4076 . PMC   7403793 . PMID   32821071.
  16. 1 2 3 Blaser MJ (October 2006). "Who are we? Indigenous microbes and the ecology of human diseases". EMBO Reports. 7 (10): 956–60. doi:10.1038/sj.embor.7400812. PMC   1618379 . PMID   17016449.
  17. ↑ Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M (August 2018). "Helicobacter pylori and extragastric diseases: A review". World Journal of Gastroenterology (Review). 24 (29): 3204–3221. doi: 10.3748/wjg.v24.i29.3204 . PMC   6079286 . PMID   30090002.
  18. ↑ Ackerman J (June 2012). "The ultimate social network". Scientific American. Vol. 306, no. 6. pp. 36–43. doi:10.1038/scientificamerican0612-36. PMID   22649992.
  19. 1 2 "Helicobacter pylori | CDC Yellow Book 2024". wwwnc.cdc.gov. Archived from the original on 22 October 2023. Retrieved 20 October 2023.
  20. 1 2 Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK (19 April 2023). "Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis". The Lancet Gastroenterology & Hepatology. 8 (6): 553–564. doi:10.1016/S2468-1253(23)00070-5. PMID   37086739. S2CID   258272798.
  21. ↑ Hooi JK, Lai WY, Ng WK, Suen MM, Underwood FE, Tanyingoh D, et al. (August 2017). "Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis". Gastroenterology. 153 (2): 420–429. doi: 10.1053/j.gastro.2017.04.022 . PMID   28456631.
  22. ↑ Goodwin CS, Armstrong JA, Chilvers T, et al. (1989). "Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively". Int. J. Syst. Bacteriol. 39 (4): 397–405. doi: 10.1099/00207713-39-4-397 .
  23. 1 2 Martínez LE, Hardcastle JM, Wang J, Pincus Z, Tsang J, Hoover TR, et al. (January 2016). "Helicobacter pylori strains vary cell shape and flagellum number to maintain robust motility in viscous environments". Mol Microbiol. 99 (1): 88–110. doi:10.1111/mmi.13218. PMC   4857613 . PMID   26365708.
  24. ↑ O'Rourke J, Bode G (2001). Morphology and Ultrastructure. ASM Press. ISBN   978-1-55581-213-3. PMID   21290748.
  25. 1 2 Kao CY, Sheu BS, Wu JJ (February 2016). "Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis". Biomedical Journal. 39 (1): 14–23. doi:10.1016/j.bj.2015.06.002. PMC   6138426 . PMID   27105595.
  26. ↑ Ierardi E, Losurdo G, Mileti A, Paolillo R, Giorgio F, Principi M, et al. (May 2020). "The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science". Antibiotics (Basel). 9 (6): 293. doi: 10.3390/antibiotics9060293 . PMC   7345126 . PMID   32486473.
  27. ↑ Olson JW, Maier RJ (November 2002). "Molecular hydrogen as an energy source for Helicobacter pylori". Science. 298 (5599): 1788–90. Bibcode:2002Sci...298.1788O. doi:10.1126/science.1077123. PMID   12459589. S2CID   27205768.
  28. 1 2 Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, et al. (December 2020). "Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment". Cells. 10 (1): 27. doi: 10.3390/cells10010027 . PMC   7824444 . PMID   33375694.
  29. ↑ Elshenawi Y, Hu S, Hathroubi S (July 2023). "Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options". Antibiotics. 12 (8): 1260. doi: 10.3390/antibiotics12081260 . PMC   10451559 . PMID   37627679.
  30. 1 2 3 4 5 6 7 8 9 10 Kusters JG, van Vliet AH, Kuipers EJ (July 2006). "Pathogenesis of Helicobacter pylori infection". Clinical Microbiology Reviews. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC   1539101 . PMID   16847081.
  31. 1 2 Alzahrani S, Lina TT, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE (September 2014). "Effect of Helicobacter pylori on gastric epithelial cells". World J Gastroenterol. 20 (36): 12767–80. doi: 10.3748/wjg.v20.i36.12767 . PMC   4177462 . PMID   25278677.
  32. ↑ "Genome information for the H. pylori 26695 and J99 strains". Institut Pasteur. 2002. Archived from the original on 26 November 2017. Retrieved 1 September 2008.
  33. ↑ "Helicobacter pylori J99, complete genome". National Center for Biotechnology Information. Archived from the original on 6 April 2011. Retrieved 1 September 2008.
  34. ↑ Oh JD, Kling-Bäckhed H, Giannakis M, Xu J, Fulton RS, Fulton LA, et al. (June 2006). "The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression". Proceedings of the National Academy of Sciences of the United States of America. 103 (26): 9999–10004. Bibcode:2006PNAS..103.9999O. doi: 10.1073/pnas.0603784103 . PMC   1480403 . PMID   16788065.
  35. ↑ "Helicobacter pylori 26695, complete genome". National Center for Biotechnology Information. Retrieved 1 September 2008.
  36. 1 2 Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, et al. (August 1997). "The complete genome sequence of the gastric pathogen Helicobacter pylori". Nature. 388 (6642): 539–47. Bibcode:1997Natur.388..539T. doi: 10.1038/41483 . PMID   9252185. S2CID   4411220.
  37. ↑ van Vliet AH (January 2017). "Use of pan-genome analysis for the identification of lineage-specific genes of Helicobacter pylori". FEMS Microbiology Letters. 364 (2): fnw296. doi: 10.1093/femsle/fnw296 . PMID   28011701.
  38. ↑ Uchiyama I, Albritton J, Fukuyo M, Kojima KK, Yahara K, Kobayashi I (9 August 2016). "A Novel Approach to Helicobacter pylori Pan-Genome Analysis for Identification of Genomic Islands". PLOS ONE. 11 (8): e0159419. Bibcode:2016PLoSO..1159419U. doi: 10.1371/journal.pone.0159419 . PMC   4978471 . PMID   27504980.
  39. 1 2 Krebes J, Morgan RD, Bunk B, Spröer C, Luong K, Parusel R, et al. (February 2014). "The complex methylome of the human gastric pathogen Helicobacter pylori". Nucleic Acids Res. 42 (4): 2415–32. doi:10.1093/nar/gkt1201. PMC   3936762 . PMID   24302578.
  40. 1 2 3 Sharma CM, Hoffmann S, Darfeuille F, Reignier J, Findeiss S, Sittka A, et al. (March 2010). "The primary transcriptome of the major human pathogen Helicobacter pylori". Nature. 464 (7286): 250–5. Bibcode:2010Natur.464..250S. doi:10.1038/nature08756. PMID   20164839. S2CID   205219639.
  41. ↑ Müller SA, Pernitzsch SR, Haange SB, Uetz P, von Bergen M, Sharma CM, et al. (3 August 2015). "Stable isotope labeling by amino acids in cell culture based proteomics reveals differences in protein abundances between spiral and coccoid forms of the gastric pathogen Helicobacter pylori". Journal of Proteomics. 126: 34–45. doi:10.1016/j.jprot.2015.05.011. ISSN   1874-3919. PMID   25979772. S2CID   415255. Archived from the original on 27 July 2021. Retrieved 26 July 2021.
  42. ↑ Wuchty S, Müller SA, Caufield JH, Häuser R, Aloy P, Kalkhof S, et al. (May 2018). "Proteome Data Improves Protein Function Prediction in the Interactome of Helicobacter pylori". Mol Cell Proteomics. 17 (5): 961–973. doi: 10.1074/mcp.RA117.000474 . PMC   5930399 . PMID   29414760.
  43. 1 2 Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. (August 2022). "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report". Gut. 71 (9): 1724–1762. doi:10.1136/gutjnl-2022-327745. PMID   35944925.
  44. 1 2 "ICD-11 for Mortality and Morbidity Statistics". icd.who.int. Archived from the original on 15 October 2023. Retrieved 9 January 2024.
  45. 1 2 3 4 5 "The Changes Made in the New Expert Consensus on H pylori". Medscape. Archived from the original on 9 January 2024. Retrieved 9 January 2024.
  46. ↑ Repetto O, Vettori R, Steffan A, Cannizzaro R, De Re V (November 2023). "Circulating Proteins as Diagnostic Markers in Gastric Cancer". Int J Mol Sci. 24 (23): 16931. doi: 10.3390/ijms242316931 . PMC   10706891 . PMID   38069253.
  47. ↑ Livzan MA, Mozgovoi SI, Gaus OV, Shimanskaya AG, Kononov AV (July 2023). "Histopathological Evaluation of Gastric Mucosal Atrophy for Predicting Gastric Cancer Risk: Problems and Solutions". Diagnostics (Basel). 13 (15): 2478. doi: 10.3390/diagnostics13152478 . PMC   10417051 . PMID   37568841.
  48. ↑ Dixon MF (February 2000). "Patterns of inflammation linked to ulcer disease". Baillière's Best Practice & Research. Clinical Gastroenterology. 14 (1): 27–40. doi:10.1053/bega.1999.0057. PMID   10749087.
  49. ↑ Mommersteeg MC, Yu BT, van den Bosch TP, von der Thüsen JH, Kuipers EJ, Doukas M, et al. (October 2022). "Constitutive programmed death ligand 1 expression protects gastric G-cells from Helicobacter pylori-induced inflammation". Helicobacter. 27 (5): e12917. doi:10.1111/hel.12917. PMC   9542424 . PMID   35899973. S2CID   251132578.
  50. 1 2 Blaser MJ, Atherton JC (February 2004). "Helicobacter pylori persistence: biology and disease". The Journal of Clinical Investigation. 113 (3): 321–33. doi:10.1172/JCI20925. PMC   324548 . PMID   14755326.
  51. ↑ Schubert ML, Peura DA (June 2008). "Control of gastric acid secretion in health and disease". Gastroenterology. 134 (7): 1842–60. doi:10.1053/j.gastro.2008.05.021. PMID   18474247. S2CID   206210451.
  52. ↑ Abbas H, Niazi M, Makker J (May 2017). "Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Colon: A Case Report and a Literature Review". The American Journal of Case Reports. 18: 491–497. doi:10.12659/AJCR.902843. PMC   5424574 . PMID   28469125.
  53. 1 2 Paydas S (April 2015). "Helicobacter pylori eradication in gastric diffuse large B cell lymphoma". World Journal of Gastroenterology. 21 (13): 3773–6. doi: 10.3748/wjg.v21.i13.3773 . PMC   4385524 . PMID   25852262.
  54. ↑ Kuipers EJ (March 1999). "Review article: exploring the link between Helicobacter pylori and gastric cancer". Alimentary Pharmacology & Therapeutics. 13 (Suppl 1): 3–11. doi:10.1046/j.1365-2036.1999.00002.x. PMID   10209681. S2CID   19231673.
  55. ↑ Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. (April 2019). "Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods". International Journal of Cancer. 144 (8): 1941–1953. doi: 10.1002/ijc.31937 . PMID   30350310.
  56. ↑ Deng JY, Liang H (April 2014). "Clinical significance of lymph node metastasis in gastric cancer". World Journal of Gastroenterology. 20 (14): 3967–75. doi: 10.3748/wjg.v20.i14.3967 . PMC   3983452 . PMID   24744586.
  57. 1 2 Valenzuela MA, Canales J, Corvalán AH, Quest AF (December 2015). "Helicobacter pylori-induced inflammation and epigenetic changes during gastric carcinogenesis". World Journal of Gastroenterology. 21 (45): 12742–56. doi: 10.3748/wjg.v21.i45.12742 . PMC   4671030 . PMID   26668499.
  58. 1 2 Raza Y, Khan A, Farooqui A, Mubarak M, Facista A, Akhtar SS, et al. (October 2014). "Oxidative DNA damage as a potential early biomarker of Helicobacter pylori associated carcinogenesis". Pathology & Oncology Research. 20 (4): 839–46. doi:10.1007/s12253-014-9762-1. PMID   24664859. S2CID   18727504.
  59. ↑ Koeppel M, Garcia-Alcalde F, Glowinski F, Schlaermann P, Meyer TF (June 2015). "Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells". Cell Reports. 11 (11): 1703–13. doi: 10.1016/j.celrep.2015.05.030 . PMID   26074077.
  60. 1 2 3 4 Markowski AR, Markowska A, Guzinska-Ustymowicz K (October 2016). "Pathophysiological and clinical aspects of gastric hyperplastic polyps". World Journal of Gastroenterology. 22 (40): 8883–8891. doi: 10.3748/wjg.v22.i40.8883 . PMC   5083793 . PMID   27833379.
  61. ↑ Dong YF, Guo T, Yang H, Qian JM, Li JN (February 2019). "[Correlations between gastric Helicobacter pylori infection and colorectal polyps or cancer]". Zhonghua Nei Ke Za Zhi (in Chinese). 58 (2): 139–142. doi:10.3760/cma.j.issn.0578-1426.2019.02.011. PMID   30704201.
  62. 1 2 Zuo Y, Jing Z, Bie M, Xu C, Hao X, Wang B (September 2020). "Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis". Medicine (Baltimore). 99 (37): e21832. doi:10.1097/MD.0000000000021832. PMC   7489651 . PMID   32925719.
  63. ↑ Papastergiou V, Karatapanis S, Georgopoulos SD (January 2016). "Helicobacter pylori and colorectal neoplasia: Is there a causal link?". World J Gastroenterol. 22 (2): 649–58. doi: 10.3748/wjg.v22.i2.649 . PMC   4716066 . PMID   26811614.
  64. 1 2 3 Debowski AW, Walton SM, Chua EG, Tay AC, Liao T, Lamichhane B, et al. (June 2017). "Helicobacter pylori gene silencing in vivo demonstrates urease is essential for chronic infection". PLOS Pathogens. 13 (6): e1006464. doi: 10.1371/journal.ppat.1006464 . PMC   5500380 . PMID   28644872.
  65. ↑ Al Quraan AM, Beriwal N, Sangay P, Namgyal T (October 2019). "The Psychotic Impact of Helicobacter pylori Gastritis and Functional Dyspepsia on Depression: A Systematic Review". Cureus. 11 (10): e5956. doi: 10.7759/cureus.5956 . PMC   6863582 . PMID   31799095.
  66. 1 2 "Helicobacter Pylori (H. Pylori) Tests: MedlinePlus Medical Test". medlineplus.gov. Archived from the original on 16 February 2024. Retrieved 16 February 2024.
  67. 1 2 "Symptoms & Causes of Peptic Ulcers (Stomach or Duodenal Ulcers) - NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Archived from the original on 17 February 2024. Retrieved 17 February 2024.
  68. ↑ Popa DG, Obleagă CV, Socea B, Serban D, Ciurea ME, Diaconescu M, et al. (October 2021). "Role of Helicobacter pylori in the triggering and evolution of hemorrhagic gastro-duodenal lesions". Exp Ther Med. 22 (4): 1147. doi:10.3892/etm.2021.10582. PMC   8392874 . PMID   34504592.
  69. ↑ Al-Azri M, Al-Kindi J, Al-Harthi T, Al-Dahri M, Panchatcharam SM, Al-Maniri A (June 2019). "Awareness of Stomach and Colorectal Cancer Risk Factors, Symptoms and Time Taken to Seek Medical Help Among Public Attending Primary Care Setting in Muscat Governorate, Oman". Journal of Cancer Education. 34 (3): 423–434. doi:10.1007/s13187-017-1266-8. ISSN   0885-8195. PMID   28782080. S2CID   4017466. Archived from the original on 24 February 2024. Retrieved 20 January 2024.
  70. ↑ Wu Q, Yang ZP, Xu P, Gao LC, Fan DM (July 2013). "Association between Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis". Colorectal Disease. 15 (7): e352-64. doi:10.1111/codi.12284. PMID   23672575. S2CID   5444584.
  71. ↑ Soetikno RM, Kaltenbach T, Rouse RV, Park W, Maheshwari A, Sato T, et al. (March 2008). "Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults". JAMA. 299 (9): 1027–35. doi: 10.1001/jama.299.9.1027 . PMID   18319413.
  72. 1 2 Yamaoka Y, Saruuljavkhlan B, Alfaray RI, Linz B (2023). "Helicobacter pylori and Gastric Cancer". Curr Top Microbiol Immunol. Current Topics in Microbiology and Immunology. 444: 117–155. doi:10.1007/978-3-031-47331-9_5. ISBN   978-3-031-47330-2. PMID   38231217.
  73. ↑ Alfarouk KO, Bashir AH, Aljarbou AN, Ramadan AM, Muddathir AK, AlHoufie ST, et al. (22 February 2019). "Helicobacter pylori in Gastric Cancer and Its Management". Frontiers in Oncology. 9: 75. doi: 10.3389/fonc.2019.00075 . PMC   6395443 . PMID   30854333.
  74. ↑ Santos JC, Ribeiro ML (August 2015). "Epigenetic regulation of DNA repair machinery in Helicobacter pylori-induced gastric carcinogenesis". World Journal of Gastroenterology. 21 (30): 9021–37. doi: 10.3748/wjg.v21.i30.9021 . PMC   4533035 . PMID   26290630.
  75. ↑ Raza Y, Ahmed A, Khan A, Chishti AA, Akhter SS, Mubarak M, et al. (May 2020). "Helicobacter pylori severely reduces expression of DNA repair proteins PMS2 and ERCC1 in gastritis and gastric cancer". DNA Repair. 89: 102836. doi: 10.1016/j.dnarep.2020.102836 . PMID   32143126.
  76. ↑ Dore MP, Pes GM, Bassotti G, Usai-Satta P (2016). "Dyspepsia: When and How to Test for Helicobacter pylori Infection". Gastroenterology Research and Practice. 2016: 8463614. doi: 10.1155/2016/8463614 . PMC   4864555 . PMID   27239194.
  77. 1 2 Muhammad JS, Eladl MA, Khoder G (February 2019). "Helicobacter pylori-induced DNA Methylation as an Epigenetic Modulator of Gastric Cancer: Recent Outcomes and Future Direction". Pathogens. 8 (1): 23. doi: 10.3390/pathogens8010023 . PMC   6471032 . PMID   30781778.
  78. 1 2 Noto JM, Peek RM (2011). "The role of microRNAs in Helicobacter pylori pathogenesis and gastric carcinogenesis". Frontiers in Cellular and Infection Microbiology. 1: 21. doi: 10.3389/fcimb.2011.00021 . PMC   3417373 . PMID   22919587.
  79. ↑ Tsuji S, Kawai N, Tsujii M, Kawano S, Hori M (July 2003). "Review article: inflammation-related promotion of gastrointestinal carcinogenesis--a perigenetic pathway". Alimentary Pharmacology & Therapeutics. 18 (Suppl 1): 82–9. doi: 10.1046/j.1365-2036.18.s1.22.x . PMID   12925144. S2CID   22646916.
  80. 1 2 Suganuma M, Yamaguchi K, Ono Y, Matsumoto H, Hayashi T, Ogawa T, et al. (July 2008). "TNF-alpha-inducing protein, a carcinogenic factor secreted from H. pylori, enters gastric cancer cells". International Journal of Cancer. 123 (1): 117–22. doi: 10.1002/ijc.23484 . PMID   18412243. S2CID   5532769.
  81. ↑ Duan Q, Zhou M, Zhu L, Zhu G (January 2013). "Flagella and bacterial pathogenicity". J Basic Microbiol. 53 (1): 1–8. doi:10.1002/jobm.201100335. PMID   22359233. S2CID   22002199.
  82. 1 2 3 Nedeljković M, Sastre DE, Sundberg EJ (July 2021). "Bacterial Flagellar Filament: A Supramolecular Multifunctional Nanostructure". Int J Mol Sci. 22 (14): 7521. doi: 10.3390/ijms22147521 . PMC   8306008 . PMID   34299141.
  83. ↑ Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, Anagreyyah S, Anajirih N, et al. (January 2023). "Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges". Antibiotics (Basel). 12 (2): 191. doi: 10.3390/antibiotics12020191 . PMC   9952126 . PMID   36830102.
  84. ↑ Petersen AM, Krogfelt KA (May 2003). "Helicobacter pylori: an invading microorganism? A review". FEMS Immunology and Medical Microbiology (Review). 36 (3): 117–26. doi: 10.1016/S0928-8244(03)00020-8 . PMID   12738380.
  85. 1 2 3 4 Testerman TL, Morris J (September 2014). "Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment". World Journal of Gastroenterology (Review). 20 (36): 12781–808. doi: 10.3748/wjg.v20.i36.12781 . PMC   4177463 . PMID   25278678.
  86. 1 2 3 Hernández VM, Arteaga A, Dunn MF (November 2021). "Diversity, properties and functions of bacterial arginases". FEMS Microbiol Rev. 45 (6). doi:10.1093/femsre/fuab034. PMID   34160574.
  87. 1 2 Li S, Zhao W, Xia L, Kong L, Yang L (2023). "How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?". Infect Drug Resist. 16: 3787–3805. doi: 10.2147/IDR.S412361 . PMC   10278649 . PMID   37342435.
  88. ↑ George G, Kombrabail M, Raninga N, Sau AK (March 2017). "Arginase of Helicobacter Gastric Pathogens Uses a Unique Set of Non-catalytic Residues for Catalysis". Biophysical Journal. 112 (6): 1120–1134. Bibcode:2017BpJ...112.1120G. doi:10.1016/j.bpj.2017.02.009. PMC   5376119 . PMID   28355540.
  89. ↑ Smoot DT (December 1997). "How does Helicobacter pylori cause mucosal damage? Direct mechanisms". Gastroenterology. 113 (6 Suppl): S31-4, discussion S50. doi: 10.1016/S0016-5085(97)80008-X . PMID   9394757.
  90. 1 2 3 Doohan D, Rezkitha YA, Waskito LA, Yamaoka Y, Miftahussurur M (July 2021). "Helicobacter pylori BabA-SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development". Toxins (Basel). 13 (7): 485. doi: 10.3390/toxins13070485 . PMC   8310295 . PMID   34357957.
  91. ↑ Rad R, Gerhard M, Lang R, Schöniger M, Rösch T, Schepp W, et al. (15 March 2002). "The Helicobacter pylori Blood Group Antigen-Binding Adhesin Facilitates Bacterial Colonization and Augments a Nonspecific Immune Response". The Journal of Immunology. 168 (6): 3033–3041. doi: 10.4049/jimmunol.168.6.3033 . PMID   11884476.
  92. ↑ Bugaytsova JA, Björnham O, Chernov YA, Gideonsson P, Henriksson S, Mendez M, et al. (March 2017). "Helicobacter pylori Adapts to Chronic Infection and Gastric Disease via pH-Responsive BabA-Mediated Adherence". Cell Host & Microbe. 21 (3): 376–389. doi:10.1016/j.chom.2017.02.013. PMC   5392239 . PMID   28279347.
  93. ↑ Mahdavi J, Sondén B, Hurtig M, Olfat FO, Forsberg L, Roche N, et al. (July 2002). "Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation". Science. 297 (5581): 573–8. Bibcode:2002Sci...297..573M. doi:10.1126/science.1069076. PMC   2570540 . PMID   12142529.
  94. ↑ Zhang L, Xie J (September 2023). "Biosynthesis, structure and biological function of cholesterol glucoside in Helicobacter pylori: A review". Medicine (Baltimore). 102 (36): e34911. doi:10.1097/MD.0000000000034911. PMC   10489377 . PMID   37682174.
  95. ↑ Ridyard KE, Overhage J (May 2021). "The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent". Antibiotics (Basel). 10 (6): 650. doi: 10.3390/antibiotics10060650 . PMC   8227053 . PMID   34072318.
  96. 1 2 Hsu CY, Yeh JY, Chen CY, Wu HY, Chiang MH, Wu CL, et al. (December 2021). "Helicobacter pylori cholesterol-α-glucosyltransferase manipulates cholesterol for bacterial adherence to gastric epithelial cells". Virulence. 12 (1): 2341–2351. doi:10.1080/21505594.2021.1969171. PMC   8437457 . PMID   34506250.
  97. ↑ Morey P, Pfannkuch L, Pang E, Boccellato F, Sigal M, Imai-Matsushima A, et al. (April 2018). "Helicobacter pylori Depletes Cholesterol in Gastric Glands to Prevent Interferon Gamma Signaling and Escape the Inflammatory Response". Gastroenterology. 154 (5): 1391–1404.e9. doi:10.1053/j.gastro.2017.12.008. hdl: 21.11116/0000-0001-3B12-9 . PMID   29273450.
  98. 1 2 Ramarao N, Gray-Owen SD, Meyer TF (October 2000). "Helicobacter pylori induces but survives the extracellular release of oxygen radicals from professional phagocytes using its catalase activity". Mol Microbiol. 38 (1): 103–13. doi:10.1046/j.1365-2958.2000.02114.x. hdl: 11858/00-001M-0000-000E-C7AD-8 . PMID   11029693.
  99. ↑ "UniProt". www.uniprot.org. Retrieved 20 March 2024.
  100. ↑ "TNF-alpha inducing protein". www.uniprot.org. Retrieved 8 April 2024.
  101. ↑ Watanabe T, Takahashi A, Suzuki K, Kurusu-Kanno M, Yamaguchi K, Fujiki H, et al. (15 May 2014). "Epithelial-mesenchymal transition in human gastric cancer cell lines induced by TNF-α-inducing protein of Helicobacter pylori: Cell migration induced by Tipα of H. pylori". International Journal of Cancer. 134 (10): 2373–2382. doi:10.1002/ijc.28582.
  102. ↑ Wallden K, Rivera-Calzada A, Waksman G (September 2010). "Type IV secretion systems: versatility and diversity in function". Cell Microbiol. 12 (9): 1203–12. doi:10.1111/j.1462-5822.2010.01499.x. PMC   3070162 . PMID   20642798.
  103. 1 2 Broutet N, Marais A, Lamouliatte H, de Mascarel A, Samoyeau R, Salamon R, et al. (April 2001). "cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia". Journal of Clinical Microbiology. 39 (4): 1319–22. doi:10.1128/JCM.39.4.1319-1322.2001. PMC   87932 . PMID   11283049.
  104. ↑ Zawilak-Pawlik A, Zarzecka U, Żyła-Uklejewicz D, Lach J, Strapagiel D, Tegtmeyer N, et al. (August 2019). "Establishment of serine protease htrA mutants in Helicobacter pylori is associated with secA mutations". Scientific Reports. 9 (1): 11794. Bibcode:2019NatSR...911794Z. doi:10.1038/s41598-019-48030-6. PMC   6692382 . PMID   31409845.
  105. ↑ Peek RM, Crabtree JE (January 2006). "Helicobacter infection and gastric neoplasia". The Journal of Pathology. 208 (2): 233–48. doi: 10.1002/path.1868 . PMID   16362989. S2CID   31718278.
  106. ↑ Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, et al. (November 2004). "Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island". Nature Immunology. 5 (11): 1166–74. doi:10.1038/ni1131. PMID   15489856. S2CID   2898805.
  107. ↑ Backert S, Selbach M (August 2008). "Role of type IV secretion in Helicobacter pylori pathogenesis". Cellular Microbiology. 10 (8): 1573–81. doi: 10.1111/j.1462-5822.2008.01156.x . PMID   18410539. S2CID   37626.
  108. ↑ Hatakeyama M (September 2004). "Oncogenic mechanisms of the Helicobacter pylori CagA protein". Nature Reviews. Cancer. 4 (9): 688–94. doi:10.1038/nrc1433. PMID   15343275. S2CID   1218835.
  109. ↑ Kim W, Moss SF (December 2008). "The role of H. pylori in the development of stomach cancer". Oncology Review. 1 (Supp l1): 165–168. Archived from the original on 20 December 2014. Retrieved 25 August 2014.
  110. ↑ "UniProt". www.uniprot.org. Retrieved 21 March 2024.
  111. ↑ Miehlke S, Yu J, Schuppler M, Frings C, Kirsch C, Negraszus N, et al. (April 2001). "Helicobacter pylori vacA, iceA, and cagA status and pattern of gastritis in patients with malignant and benign gastroduodenal disease". The American Journal of Gastroenterology. 96 (4): 1008–13. doi:10.1111/j.1572-0241.2001.03685.x. PMID   11316139. S2CID   24024542. Archived from the original on 23 February 2022. Retrieved 24 June 2020.
  112. 1 2 Hisatsune J, Yamasaki E, Nakayama M, Shirasaka D, Kurazono H, Katagata Y, et al. (September 2007). "Helicobacter pylori VacA enhances prostaglandin E2 production through induction of cyclooxygenase 2 expression via a p38 mitogen-activated protein kinase/activating transcription factor 2 cascade in AZ-521 cells". Infect Immun. 75 (9): 4472–81. doi:10.1128/IAI.00500-07. PMC   1951161 . PMID   17591797.
  113. ↑ Capurro MI, Greenfield LK, Prashar A, Xia S, Abdullah M, Wong H, et al. (August 2019). "VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1". Nature Microbiology. 4 (8): 1411–1423. doi:10.1038/s41564-019-0441-6. PMC   6938649 . PMID   31110360.
  114. ↑ Sajib S, Zahra FT, Lionakis MS, German NA, Mikelis CM (February 2018). "Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions". Angiogenesis. 21 (1): 1–14. doi:10.1007/s10456-017-9583-4. PMID   29110215. S2CID   3346742.
  115. ↑ da Costa DM, Pereira Edos S, Rabenhorst SH (October 2015). "What exists beyond cagA and vacA? Helicobacter pylori genes in gastric diseases". World J Gastroenterol. 21 (37): 10563–72. doi: 10.3748/wjg.v21.i37.10563 . PMC   4588078 . PMID   26457016.
  116. ↑ Dumrese C, Slomianka L, Ziegler U, Choi SS, Kalia A, Fulurija A, et al. (May 2009). "The secreted Helicobacter cysteine-rich protein A causes adherence of human monocytes and differentiation into a macrophage-like phenotype". FEBS Letters. 583 (10): 1637–43. doi:10.1016/j.febslet.2009.04.027. PMC   2764743 . PMID   19393649.
  117. ↑ Alam J, Sarkar A, Karmakar BC, Ganguly M, Paul S, Mukhopadhyay AK (August 2020). "Novel virulence factor dupA of Helicobacter pylori as an important risk determinant for disease manifestation: An overview". World J Gastroenterol. 26 (32): 4739–4752. doi: 10.3748/wjg.v26.i32.4739 . PMC   7459207 . PMID   32921954.
  118. ↑ Olczak AA, Olson JW, Maier RJ (June 2002). "Oxidative-stress resistance mutants of Helicobacter pylori". Journal of Bacteriology. 184 (12): 3186–93. doi:10.1128/JB.184.12.3186-3193.2002. PMC   135082 . PMID   12029034.
  119. 1 2 3 Trastoy R, Manso T, Fernández-García L, Blasco L, Ambroa A, Pérez Del Molino ML, et al. (October 2018). "Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments". Clin Microbiol Rev. 31 (4). doi:10.1128/CMR.00023-18. PMC   6148185 . PMID   30068737.
  120. ↑ O'Rourke EJ, Chevalier C, Pinto AV, Thiberge JM, Ielpi L, Labigne A, et al. (March 2003). "Pathogen DNA as target for host-generated oxidative stress: role for repair of bacterial DNA damage in Helicobacter pylori colonization". Proceedings of the National Academy of Sciences of the United States of America. 100 (5): 2789–94. Bibcode:2003PNAS..100.2789O. doi: 10.1073/pnas.0337641100 . PMC   151419 . PMID   12601164.
  121. ↑ Michod RE, Bernstein H, Nedelcu AM (May 2008). "Adaptive value of sex in microbial pathogens". Infection, Genetics and Evolution. 8 (3): 267–85. doi:10.1016/j.meegid.2008.01.002. PMID   18295550.
  122. ↑ Bahmaninejad P, Ghafourian S, Mahmoudi M, Maleki A, Sadeghifard N, Badakhsh B (April 2021). "Persister cells as a possible cause of antibiotic therapy failure in Helicobacter pylori". JGH Open. 5 (4): 493–497. doi:10.1002/jgh3.12527. PMC   8035453 . PMID   33860100.
  123. ↑ Cammarota G, Sanguinetti M, Gallo A, Posteraro B (August 2012). "Review article: biofilm formation by H elicobacter pylori as a target for eradication of resistant infection". Alimentary Pharmacology & Therapeutics. 36 (3): 222–230. doi:10.1111/j.1365-2036.2012.05165.x. PMID   22650647. S2CID   24026187 . Retrieved 3 March 2024.
  124. 1 2 3 Dorer MS, Fero J, Salama NR (July 2010). Blanke SR (ed.). "DNA damage triggers genetic exchange in Helicobacter pylori". PLOS Pathogens. 6 (7): e1001026. doi: 10.1371/journal.ppat.1001026 . PMC   2912397 . PMID   20686662.
  125. ↑ Ailloud F, Didelot X, Woltemate S, Pfaffinger G, Overmann J, Bader RC, et al. (May 2019). "Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps". Nat Commun. 10 (1): 2273. doi:10.1038/s41467-019-10050-1. PMC   6531487 . PMID   31118420.
  126. ↑ Loughlin MF, Barnard FM, Jenkins D, Sharples GJ, Jenks PJ (April 2003). "Helicobacter pylori mutants defective in RuvC Holliday junction resolvase display reduced macrophage survival and spontaneous clearance from the murine gastric mucosa". Infection and Immunity. 71 (4): 2022–31. doi:10.1128/IAI.71.4.2022-2031.2003. PMC   152077 . PMID   12654822.
  127. 1 2 Wang G, Maier RJ (January 2008). "Critical role of RecN in recombinational DNA repair and survival of Helicobacter pylori". Infection and Immunity. 76 (1): 153–60. doi:10.1128/IAI.00791-07. PMC   2223656 . PMID   17954726.
  128. 1 2 3 4 5 6 Crowe SE (21 March 2019). "Helicobacter pylori Infection". New England Journal of Medicine. 380 (12): 1158–1165. doi:10.1056/NEJMcp1710945. PMID   30893536. S2CID   84843669.
  129. 1 2 Jambi LK (7 October 2022). "Systematic Review and Meta-Analysis on the Sensitivity and Specificity of (13)C/(14)C-Urea Breath Tests in the Diagnosis of Helicobacter pylori Infection". Diagnostics. 12 (10): 2428. doi: 10.3390/diagnostics12102428 . PMC   9600925 . PMID   36292117.
  130. ↑ Logan RP, Walker MM (October 2001). "ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection". BMJ. 323 (7318): 920–2. doi:10.1136/bmj.323.7318.920. PMC   1121445 . PMID   11668141.
  131. ↑ Reshetnyak VI, Burmistrov AI, Maev IV (February 2021). "Helicobacter pylori: Commensal, symbiont or pathogen?". World J Gastroenterol. 27 (7): 545–560. doi: 10.3748/wjg.v27.i7.545 . PMC   7901052 . PMID   33642828.
  132. ↑ Delport W, van der Merwe SW (2007). "The transmission of Helicobacter pylori: the effects of analysis method and study population on inference". Best Practice & Research. Clinical Gastroenterology. 21 (2): 215–36. doi:10.1016/j.bpg.2006.10.001. hdl: 2263/4083 . PMID   17382274.
  133. ↑ Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X (August 2017). "Prevention of Gastric Cancer: Eradication of Helicobacter Pylori and Beyond". International Journal of Molecular Sciences. 18 (8): 1699. doi: 10.3390/ijms18081699 . PMC   5578089 . PMID   28771198.
  134. ↑ Li L, Yu C (2019). "Helicobacter pylori Infection following Endoscopic Resection of Early Gastric Cancer". BioMed Research International. 2019: 9824964. doi: 10.1155/2019/9824964 . PMC   6816031 . PMID   31737682.
  135. 1 2 Talebi Bezmin Abadi A (March 2016). "Vaccine against Helicobacter pylori: Inevitable approach". World J Gastroenterol. 22 (11): 3150–7. doi: 10.3748/wjg.v22.i11.3150 . PMC   4789989 . PMID   27003991.
  136. ↑ Blanchard TG, Nedrud JG (2010). "9. Helicobacter pylori Vaccines". In Sutton P, Mitchell H (eds.). Helicobacter pylori in the 21st Century. CABI. pp. 167–189. ISBN   978-1-84593-594-8 . Retrieved 7 August 2013.
  137. ↑ de Vries R, Klok RM, Brouwers JR, Postma MJ (February 2009). "Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health". Vaccine. 27 (6): 846–52. doi:10.1016/j.vaccine.2008.11.081. PMID   19084566. Archived from the original on 10 May 2021. Retrieved 7 August 2013.
  138. ↑ Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J (October 2009). "Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States". The Journal of Infectious Diseases. 200 (8): 1311–7. doi: 10.1086/605845 . PMID   19751153.
  139. 1 2 Sutton P, Boag JM (November 2019). "Status of vaccine research and development for Helicobacter pylori". Vaccine. 37 (50): 7295–7299. doi:10.1016/j.vaccine.2018.01.001. PMC   6892279 . PMID   29627231.
  140. ↑ "PDB101: Molecule of the Month: Proton-Gated Urea Channel". RCSB: PDB-101. Archived from the original on 6 November 2023. Retrieved 6 November 2023.
  141. 1 2 3 Azer SA, Akhondi H (2019). "Gastritis". StatPearls. PMID   31334970.
  142. 1 2 Burkitt MD, Duckworth CA, Williams JM, Pritchard DM (February 2017). "Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models". Disease Models & Mechanisms. 10 (2): 89–104. doi:10.1242/dmm.027649. PMC   5312008 . PMID   28151409.
  143. 1 2 Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. (European Helicobacter Study Group) (May 2012). "Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report". Gut. 61 (5): 646–64. doi: 10.1136/gutjnl-2012-302084 . hdl: 1765/64813 . PMID   22491499. S2CID   1401974. Archived from the original on 4 July 2021. Retrieved 7 December 2012.
  144. ↑ "Two New Regimens Win FDA Approval for H. Pylori Infection". www.medpagetoday.com. 4 May 2022. Archived from the original on 25 March 2023. Retrieved 25 March 2023.
  145. ↑ Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR (August 2017). "The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors". Current Gastroenterology Reports. 19 (8): 42. doi:10.1007/s11894-017-0577-6. PMC   5621514 . PMID   28733944.
  146. 1 2 Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. (June 2007). "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report". Gut. 56 (6): 772–81. doi:10.1136/gut.2006.101634. PMC   1954853 . PMID   17170018.
  147. ↑ Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. (European Helicobacter and microbiota study group and consensus panel) (January 2017). "Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report". Gut. 66 (1): 6–30. doi: 10.1136/gutjnl-2016-312288 . PMID   27707777. S2CID   52868868.
  148. ↑ Rauws EA, Tytgat GN (May 1990). "Cure of duodenal ulcer associated with eradication of Helicobacter pylori". Lancet. 335 (8700): 1233–5. doi:10.1016/0140-6736(90)91301-P. PMID   1971318. S2CID   41888935.
  149. ↑ Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD (August 1991). "Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial". Annals of Internal Medicine. 115 (4): 266–9. doi:10.7326/0003-4819-115-4-266. PMID   1854110.
  150. ↑ Soto SM (April 2013). "Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm". Virulence. 4 (3): 223–9. doi:10.4161/viru.23724. PMC   3711980 . PMID   23380871.
  151. 1 2 Cai Y, Wang C, Chen Z, Xu Z, Li H, Li W, et al. (August 2020). "Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux". Helicobacter. 25 (4): e12715. doi:10.1111/hel.12715. PMID   32548895. S2CID   219726485. Archived from the original on 15 February 2024. Retrieved 15 February 2024.
  152. ↑ Pohl D, Keller PM, Bordier V, Wagner K (August 2019). "Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing". World J Gastroenterol. 25 (32): 4629–4660. doi: 10.3748/wjg.v25.i32.4629 . PMC   6718044 . PMID   31528091.
  153. ↑ Sukri A, Hanafiah A, Patil S, Lopes BS (April 2023). "The Potential of Alternative Therapies and Vaccine Candidates against Helicobacter pylori". Pharmaceuticals (Basel). 16 (4): 552. doi: 10.3390/ph16040552 . PMC   10141204 . PMID   37111309.
  154. 1 2 3 Vaou N, Stavropoulou E, Voidarou C, Tsigalou C, Bezirtzoglou E (September 2021). "Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives". Microorganisms. 9 (10): 2041. doi: 10.3390/microorganisms9102041 . PMC   8541629 . PMID   34683362.
  155. ↑ Moon JK, Kim JR, Ahn YJ, Shibamoto T (June 2010). "Analysis and anti-Helicobacter activity of sulforaphane and related compounds present in broccoli ( Brassica oleracea L.) sprouts". Journal of Agricultural and Food Chemistry. 58 (11): 6672–7. doi:10.1021/jf1003573. PMID   20459098.
  156. ↑ Sathianarayanan S, Ammanath AV, Biswas R, B A, Sukumaran S, Venkidasamy B (July 2022). "A new approach against Helicobacter pylori using plants and its constituents: A review study". Microb Pathog. 168: 105594. doi:10.1016/j.micpath.2022.105594. PMID   35605740. S2CID   248975163.
  157. ↑ Stenström B, Mendis A, Marshall B (August 2008). "Helicobacter pylori--the latest in diagnosis and treatment". Australian Family Physician. 37 (8): 608–12. PMID   18704207.
  158. ↑ Fischbach L, Evans EL (August 2007). "Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori". Alimentary Pharmacology & Therapeutics (Meta-analysis). 26 (3): 343–57. doi:10.1111/j.1365-2036.2007.03386.x. PMID   17635369. S2CID   20973127.
  159. ↑ Graham DY, Shiotani A (June 2008). "New concepts of resistance in the treatment of Helicobacter pylori infections". Nature Clinical Practice. Gastroenterology & Hepatology. 5 (6): 321–31. doi:10.1038/ncpgasthep1138. PMC   2841357 . PMID   18446147.
  160. ↑ William C, Leontiadis G (February 2017). "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection". The American Journal of Gastroenterology. 112 (2): 212–239. doi:10.1038/ajg.2016.563. PMID   28071659. S2CID   9390953. Archived from the original on 12 February 2021. Retrieved 1 December 2021.
  161. ↑ Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D (November 2007). "Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance". Digestive and Liver Disease. 39 (11): 1001–5. doi:10.1016/j.dld.2007.06.016. PMID   17889627.
  162. ↑ Hsu PI, Wu DC, Chen A, Peng NJ, Tseng HH, Tsay FW, et al. (June 2008). "Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures". European Journal of Clinical Investigation. 38 (6): 404–9. doi:10.1111/j.1365-2362.2008.01951.x. PMID   18435764. S2CID   205290582.
  163. ↑ Zhu LB, Zhang YC, Huang HH, Lin J (September 2021). "Prospects for clinical applications of butyrate-producing bacteria". World J Clin Pediatr. 10 (5): 84–92. doi: 10.5409/wjcp.v10.i5.84 . PMC   8465514 . PMID   34616650.
  164. ↑ Saracino IM, Pavoni M, Saccomanno L, Fiorini G, Pesci V, Foschi C, et al. (May 2020). "Antimicrobial Efficacy of Five Probiotic Strains Against Helicobacter pylori". Antibiotics (Basel). 9 (5): 244. doi: 10.3390/antibiotics9050244 . PMC   7277513 . PMID   32403331.
  165. ↑ Rahat M, Saqib M, Ahmed M, Suleman M, Ismail SM, Mumtaz H, et al. (June 2023). "Use of eradication therapy in adjunction to periodontal therapy versus alone for treatment of Helicobacter pylori infections: a mini review". Ann Med Surg (Lond). 85 (6): 2756–2760. doi:10.1097/MS9.0000000000000741. PMC   10289787 . PMID   37363585.
  166. 1 2 Laird-Fick HS, Saini S, Hillard JR (August 2016). "Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts". Postgraduate Medical Journal. 92 (1090): 471–7. doi:10.1136/postgradmedj-2016-133997. PMID   27222587. S2CID   20739020.
  167. ↑ Badgwell B, Das P, Ajani J (August 2017). "Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy". Journal of Hematology & Oncology. 10 (1): 149. doi: 10.1186/s13045-017-0517-9 . PMC   5558742 . PMID   28810883.
  168. ↑ Bron D, Meuleman N (September 2019). "Marginal zone lymphomas: second most common lymphomas in older patients". Current Opinion in Oncology. 31 (5): 386–393. doi:10.1097/CCO.0000000000000554. PMID   31246587. S2CID   195765608.
  169. ↑ Kobayashi T, Takahashi N, Hagiwara Y, Tamaru J, Kayano H, Jin-nai I, et al. (January 2008). "Successful radiotherapy in a patient with primary rectal mucosa-associated lymphoid tissue lymphoma without the API2-MALT1 fusion gene: a case report and review of the literature". Leukemia Research. 32 (1): 173–5. doi:10.1016/j.leukres.2007.04.017. PMID   17570523.
  170. ↑ Matysiak-Budnik T, Priadko K, Bossard C, Chapelle N, Ruskoné-Fourmestraux A (July 2023). "Clinical Management of Patients with Gastric MALT Lymphoma: A Gastroenterologist's Point of View". Cancers (Basel). 15 (15): 3811. doi: 10.3390/cancers15153811 . PMC   10417821 . PMID   37568627.
  171. ↑ Casulo C, Friedberg J (2017). "Transformation of marginal zone lymphoma (and association with other lymphomas)". Best Practice & Research. Clinical Haematology. 30 (1–2): 131–138. doi:10.1016/j.beha.2016.08.029. PMID   28288708.
  172. 1 2 3 Kuo SH, Yeh KH, Chen LT, Lin CW, Hsu PN, Hsu C, et al. (June 2014). "Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity". Blood Cancer Journal. 4 (6): e220. doi:10.1038/bcj.2014.40. PMC   4080211 . PMID   24949857.
  173. 1 2 3 Cheng Y, Xiao Y, Zhou R, Liao Y, Zhou J, Ma X (August 2019). "Prognostic significance of helicobacter pylori-infection in gastric diffuse large B-cell lymphoma". BMC Cancer. 19 (1): 842. doi: 10.1186/s12885-019-6067-5 . PMC   6712724 . PMID   31455250.
  174. ↑ Tsai HJ, Tai JJ, Chen LT, Wu MS, Yeh KH, Lin CW, et al. (July 2020). "A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue". Haematologica. 105 (7): e349–e354. doi: 10.3324/haematol.2019.228775 . PMC   7327622 . PMID   31727764.
  175. ↑ Balendra V, Amoroso C, Galassi B, Esposto J, Bareggi C, Luu J, et al. (August 2023). "High-Salt Diet Exacerbates H. pylori Infection and Increases Gastric Cancer Risks". J Pers Med. 13 (9): 1325. doi: 10.3390/jpm13091325 . PMC   10533117 . PMID   37763093.
  176. ↑ Jaroenlapnopparat A, Bhatia K, Coban S (June 2022). "Inflammation and Gastric Cancer". Diseases. 10 (3): 35. doi: 10.3390/diseases10030035 . PMC   9326573 . PMID   35892729.
  177. ↑ Park JM, Han YM, Oh JY, Lee DY, Choi SH, Hahm KB (September 2021). "Transcriptome profiling implicated in beneficiary actions of kimchi extracts against Helicobacter pylori infection". J Clin Biochem Nutr. 69 (2): 171–187. doi:10.3164/jcbn.20-116. PMC   8482382 . PMID   34616109.
  178. 1 2 Brown LM (2000). "Helicobacter pylori: epidemiology and routes of transmission". Epidemiologic Reviews. 22 (2): 283–97. doi: 10.1093/oxfordjournals.epirev.a018040 . PMID   11218379.
  179. ↑ Pacifico L, Osborn JF, Bonci E, Romaggioli S, Baldini R, Chiesa C (January 2014). "Probiotics for the treatment of Helicobacter pylori infection in children". World J Gastroenterol. 20 (3): 673–83. doi: 10.3748/wjg.v20.i3.673 . PMC   3921477 . PMID   24574741.
  180. ↑ Goodman KJ, O'rourke K, Day RS, Wang C, Nurgalieva Z, Phillips CV, et al. (December 2005). "Dynamics of Helicobacter pylori infection in a US-Mexico cohort during the first two years of life". International Journal of Epidemiology. 34 (6): 1348–55. doi: 10.1093/ije/dyi152 . PMID   16076858.
  181. ↑ Li R, Zhang P, Hu Z, Yi Y, Chen L, Zhang H (14 May 2021). "Helicobacter pylori reinfection and its risk factors after initial eradication: A protocol for systematic review and meta-analysis". Medicine. 100 (19): e25949. doi: 10.1097/MD.0000000000025949 . PMC   8133036 . PMID   34106668.
  182. 1 2 3 Blaser MJ (February 2005). "An endangered species in the stomach". Scientific American. 292 (2): 38–45. Bibcode:2005SciAm.292b..38B. doi:10.1038/scientificamerican0205-38. PMID   15715390.
  183. ↑ Graham DY, Yamaoka Y, Malaty HM (November 2007). "Contemplating the future without Helicobacter pylori and the dire consequences hypothesis". Helicobacter. 12 (Suppl 2): 64–8. doi:10.1111/j.1523-5378.2007.00566.x. PMC   3128250 . PMID   17991179.
  184. ↑ Delaney B, McColl K (August 2005). "Review article: Helicobacter pylori and gastro-oesophageal reflux disease". Alimentary Pharmacology & Therapeutics (Review). 22 (Suppl 1): 32–40. doi:10.1111/j.1365-2036.2005.02607.x. PMID   16042657. S2CID   34921548.
  185. ↑ Blaser MJ, Chen Y, Reibman J (May 2008). "Does Helicobacter pylori protect against asthma and allergy?". Gut. 57 (5): 561–7. doi:10.1136/gut.2007.133462. PMC   3888205 . PMID   18194986.
  186. ↑ Chen Y, Blaser MJ (August 2008). "Helicobacter pylori colonization is inversely associated with childhood asthma". The Journal of Infectious Diseases. 198 (4): 553–60. doi:10.1086/590158. PMC   3902975 . PMID   18598192.
  187. ↑ Smoak BL, Kelley PW, Taylor DN (March 1994). "Seroprevalence of Helicobacter pylori infections in a cohort of US Army recruits". American Journal of Epidemiology. 139 (5): 513–9. doi:10.1093/oxfordjournals.aje.a117034. PMID   8154475.
  188. ↑ Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G (April 2000). "Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States". The Journal of Infectious Diseases. 181 (4): 1359–63. doi: 10.1086/315384 . PMID   10762567.
  189. ↑ Malaty HM (2007). "Epidemiology of Helicobacter pylori infection". Best Practice & Research. Clinical Gastroenterology. 21 (2): 205–14. doi:10.1016/j.bpg.2006.10.005. PMID   17382273.
  190. ↑ Mégraud F (September 2004). "H pylori antibiotic resistance: prevalence, importance, and advances in testing". Gut. 53 (9): 1374–84. doi:10.1136/gut.2003.022111. PMC   1774187 . PMID   15306603.
  191. ↑ Correa P, Piazuelo MB (January 2012). "Evolutionary History of the Helicobacter pylori Genome: Implications for Gastric Carcinogenesis". Gut and Liver. 6 (1): 21–8. doi: 10.5009/gnl.2012.6.1.21 . PMC   3286735 . PMID   22375167.
  192. ↑ Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, et al. (February 2007). "An African origin for the intimate association between humans and Helicobacter pylori". Nature. 445 (7130): 915–918. Bibcode:2007Natur.445..915L. doi:10.1038/nature05562. PMC   1847463 . PMID   17287725.
  193. ↑ "The Nobel Prize in Physiology or Medicine 2005". Archived from the original on 23 May 2020. Retrieved 30 August 2018.
  194. ↑ Bizzozero G (1893). "Ueber die schlauchförmigen Drüsen des Magendarmkanals und die Beziehungen ihres Epitheles zu dem Oberflächenepithel der Schleimhaut". Archiv für Mikroskopische Anatomie. 42: 82–152. doi:10.1007/BF02975307. S2CID   85338121. Archived from the original on 2 December 2020. Retrieved 29 June 2019.
  195. ↑ Konturek JW (December 2003). "Discovery by Jaworski of Helicobacter pylori and its pathogenetic role in peptic ulcer, gastritis and gastric cancer" (PDF). Journal of Physiology and Pharmacology. 54 (Suppl 3): 23–41. PMID   15075463. Archived from the original (PDF) on 30 September 2004. Retrieved 25 August 2008.
  196. ↑ Egan BJ, O'Morain CA (2007). "A historical perspective of Helicobacter gastroduodenitis and its complications". Best Practice & Research. Clinical Gastroenterology. 21 (2): 335–46. doi:10.1016/j.bpg.2006.12.002. PMID   17382281.
  197. ↑ Palmer ED (August 1954). "Investigation of the gastric mucosa spirochetes of the human". Gastroenterology. 27 (2): 218–20. doi:10.1016/S0016-5085(19)36173-6. PMID   13183283.
  198. ↑ Steer HW (August 1975). "Ultrastructure of cell migration throught[sic] the gastric epithelium and its relationship to bacteria". Journal of Clinical Pathology. 28 (8): 639–46. doi:10.1136/jcp.28.8.639. PMC   475793 . PMID   1184762.
  199. ↑ Marshall BJ, Warren JR (June 1984). "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration". Lancet. 1 (8390): 1311–5. doi:10.1016/S0140-6736(84)91816-6. PMID   6145023. S2CID   10066001.
  200. ↑ Atwood KI (2004). "Bacteria, Ulcers, and Ostracism? H. pylori and the making of a myth". Archived from the original on 5 November 2009. Retrieved 2 August 2008.
  201. ↑ Helicobacter pylori in peptic ulcer disease (Report). NIH Consensus Statement Online. Vol. 12. 7–9 January 1994. pp. 1–23. Archived from the original on 19 August 2011. Retrieved 21 December 2004.
  202. 1 2 Liddell HG, Scott R (1966). A Lexicon: Abridged from Liddell and Scott's Greek-English Lexicon . Oxford, UK: Oxford University Press. ISBN   978-0-19-910207-5.
  203. ↑ Marshall BS, Goodwin CS (1987). "Revised nomenclature of Campylobacter pyloridis". International Journal of Systematic Bacteriology. 37 (1): 68. doi: 10.1099/00207713-37-1-68 .
  204. ↑ Goodwin CS, Armstrong JA, Chilvers T, Peters M, Collins MD, Sly L, et al. (1989). "Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov. respectively". International Journal of Systematic Bacteriology. 39 (4): 397–405. doi: 10.1099/00207713-39-4-397 .
  205. ↑ Buckley MJ, O'Morain CA (1998). "Helicobacter biology--discovery". British Medical Bulletin. 54 (1): 7–16. doi: 10.1093/oxfordjournals.bmb.a011681 . PMID   9604426.
  206. ↑ Mégraud F, et al. (European Helicobacter Study Group) (November 2007). "Evolution of Helicobacter pylori research as observed through the workshops of the European Helicobacter Study Group". Helicobacter. 12 Suppl 2 (Suppl 2): 1–5. doi:10.1111/j.1523-5378.2007.00581.x. PMID   17991169. S2CID   45841196.
  207. ↑ "EHMSG". Ehmsg2019. Archived from the original on 11 January 2024. Retrieved 11 January 2024.
  208. ↑ Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. (European Helicobacter Pylori Study Group (EHPSG)) (February 2002). "Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report". Alimentary Pharmacology & Therapeutics. 16 (2): 167–80. doi:10.1046/j.1365-2036.2002.01169.x. PMID   11860399. S2CID   6166458.
  209. ↑ Malfertheiner P, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. (European Helicobacter Pylori Study Group (EHPSG)) (January 1997). "Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG)". European Journal of Gastroenterology & Hepatology. 9 (1): 1–2. doi:10.1097/00042737-199701000-00002. PMID   9031888. S2CID   36930542.
  210. ↑ McNicholl AG, Gasbarrini A, Tepes B, et al. (September 2014). "Pan-European registry on H. pylori management (Hp-EuReg): Interim analysis of 5,792 patients". Helicobacter. 2014: 69.
  211. ↑ "Management of Helicobacter pylori infection". Online courses. United European Gastroenterology. Archived from the original on 2 April 2015.
  212. ↑ "Annual Report 2012". United European Gastroenterology. Archived from the original on 4 June 2016. Retrieved 25 February 2015.
  213. ↑ Jung SW, Lee SW (January 2016). "The antibacterial effect of fatty acids on Helicobacter pylori infection". The Korean Journal of Internal Medicine (Review). 31 (1): 30–5. doi:10.3904/kjim.2016.31.1.30. PMC   4712431 . PMID   26767854.
Listen to this article (28 minutes)
Sound-icon.svg
This audio file was created from a revision of this article dated 24 February 2009 (2009-02-24), and does not reflect subsequent edits.
(Audio help  · More spoken articles)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.